Improving target assessment in biomedical research: the GOT-IT recommendations

In the format provided by the authors and unedited
| Project    | Member                          | Affiliation                                                                 |
|------------|---------------------------------|-----------------------------------------------------------------------------|
| AKAP18-PKA | Enno Klussmann                  | Max-Delbrück-Centrum für Molekulare Medizin                                 |
|            | Roderich Süßmuth                | Technische Universität Berlin                                               |
|            | John Weston                     | Medicinal Chemistry and Scientific Consultant                              |
| BlockCAD   | Heribert Schunkert              | Department of Cardiology, German Heart Centre Munich, Technical University Munich, and DZHK (German Centre for Cardiovascular Research), Partner site Munich, Munich Heart Alliance, all in Munich, Germany |
|            | Philip Gribbon                  | Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie          |
| CANCER     | Elmar Wolf                      | Theodor Boveri Institute, University of Würzburg                           |
|            | Stefan Knapp                    | Johann Wolfgang Goethe-Universität Frankfurt am Main                         |
|            | Peter Staller                   | Therapeutic Research, Nuvisan ICB GmbH                                      |
| ComboMiR   | Stephan Herzig                  | Helmholtz Diabetes Center HDC                                               |
|            | Matthias Blüher                  | Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig |
|            | Peter Nawroth                   | Universitätssklinikum Heidelberg                                           |
|            | Werner Kramer                   | Biomedical and Scientific Consulting                                        |
| CONNEXIN   | Christa Müller                  | PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn |
|            | Christian Steinhäuser           | Institute of Cellular Neurosciences, University of Bonn                     |
|            | Morten Grunnet                  | H. Lundbeck A/S, Valby, Denmark                                             |
| EnVision   | Ronald Kühne                    | Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. |
|            | Hans-Günther Schmalz            | Universität zu Köln                                                          |
|            | Rainer Metternich               | Berlin                                                                      |
| GOT-IT     | Christoph Emmerich              | PAASP GmbH Heidelberg                                                       |
|            | Lorena Martinez Gamboa          | Department of Experimental Neurology, Charité Berlin; QUEST Center for Transforming Biomedical Research, Berlin Institute of Health |
|            | Martine Hofmann                 | Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine & Pharmacology |
|            | Marc Bonin-Andresen             | Department of Experimental Neurology, Charité Berlin                         |
|            | Olga Arbach                     | Department of Experimental Neurology, Charité Berlin; SPARK - Validation Fund, Berlin Institute of Health, Germany |
|            | Pascal Schendel                 | Department of Experimental Neurology, Charité Berlin                         |
|            | Björn Gerlach                   | PAASP GmbH Heidelberg                                                       |
|            | Anton Bepsalov                  | PAASP GmbH Heidelberg; Pavlov Medical University, St. Petersburg, Russia    |
|            | Ulrich Dirnagl                  | Department of Experimental Neurology, Charité Berlin; QUEST Center for Transforming Biomedical Research, Berlin Institute of Health |

Supplementary Table 1 | Members of the BMBF-Target Validation Initiative (for each project)
| Research, Berlin Institute of Health |
|--------------------------------------|
| Michael J. Parnham                  |
| Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine & Pharmacology |

**GPS-TBT**

| Wolfgang Wohleben                |
|----------------------------------|
| Eberhard Karls Universität Tübingen |
| Agnieszka Bera                   |
| Eberhard Karls Universität Tübingen |
| Norbert Reiling                  |
| Forschungszentrum Borstel, Leibniz Lungenzentrum |
| Felix Hausch                     |
| Technische Universität Darmstadt |
| Heike Brötz-Oesterhelt           |
| Eberhard Karls Universität Tübingen |

**PayLOAD**

| Christiane Smerling              |
|----------------------------------|
| 3B Pharmaceuticals GmbH, Berlin  |
| Ulrich Reineke                   |
| 3B Pharmaceuticals GmbH, Berlin  |
| Stefan Müllner                   |
| fundamenta Life Science GmbH, Erkrath |

**PyrBac**

| Knut Ohlsen                      |
|----------------------------------|
| Julius-Maximilians-Universität Würzburg |
| Andreas Hilgeroth                |
| Martin-Luther-Universität Halle-Wittenberg |
| Michael Lalk                     |
| Universität Greifswald           |
| Klaus-Peter Koller               |
| SciBioCon, Bad Soden and University of Frankfurt, Molecular Biosciences |
| Reinhard Kirsch                  |
| rkph-consult, Braunschweig       |

**TANSTABB**

| Philipp Mergenthaler             |
| Charité - Universitätmedizin Berlin |
| Harald Stachelscheid             |
| Charité - Universitätmedizin Berlin and Berlin Institute of Health |
| David Andrews                    |
| Sunnybrook Research Institute, University of Toronto |

**Victori**

| Hannelore Meyer                  |
| Technische Universität München   |
| Mark Brönstrup                   |
| Helmholtz-Zentrum für Infektionsforschung GmbH |
| Michael Sattler                  |
| Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Grzegorz Popowicz                |
| Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
| Peter Sennhenn                   |
| trans MedChem Consulting         |
The Target Assessment Project Plan (TAPP) defines the overall goals of a target assessment project and outlines the strategy needed to achieve the goals specified. The clear definition and articulation of a TAPP can help focus the work of the project team. As a general rule, projects tend to require input from several key areas and are best served when interactive discussions between regulatory, clinical, toxicological and pharmacological experts are included. This ensures that all perspectives are considered early in the process and that goals are clearly set in a broad sense.

**Target Assessment Project Plan**

| Goals and expectations | Answer/Comment |
|------------------------|----------------|
| **Indication and usage** | What is the indication/disease/condition of interest? |
|                        | What is the medical need? |
|                        | What will be the final drug product or treatment approach? |
|                        | Is it for treatment or prevention? |
| **Patient Population**  | Does a defined patient population exist? |
| **Innovation**          | Are other drugs currently in use for treatment of the same clinical indication? |
| **Adverse Reactions**   | What adverse effects might be expected in response to the target class? |
|                        | What adverse reactions have been observed in clinical studies? |
|                        | What is the minimum safety profile which can be accepted? |
| **Project goals**       | What are project milestones? |
|                        | What are project endpoints/outcomes? |
|                        | What is the drug discovery value chain endpoint of this project? |
| **Critical Path**       | Answer/Comment |
| **For each chosen Assessment Block** | What are key experiments for decision-making? |
|                        | How can the Level of Confidence for decision-making be maximized? |
|                        | What are Go/NoGo decision criteria? |
|                        | Can tasks/goals be achieved with resources available? If not, what is the most meaningful compromise (and why)? |
|                        | What are critical Quality Requirements for this Assessment Block? |
Supplementary Box 1 | **Experimental approach questions: target–disease linkage**

**Causal relationships**
1. Is the target expressed in relevant human cells/tissue (i.e. within the anticipated patient population)?
2. Does the target expression vary with disease severity or progression?
3. Can published results in support or against the causality be identified and their strengths and limitations be specified?
4. If the association is genetic, is there an equivalent modification at the target level (e.g. RNA or protein level) or target activity level (e.g. activating mutations in cancer) in diseased tissues?
5. Does dysregulation of target lead to the disease phenotype? (e.g. can a temporal relationship be established? Can a dose-response relationship be established?)
6. Can the influence of any confounding factors be excluded?
7. Are data sets to establish causality based on observational studies or prospectively planned experiments?
8. Is an association of the target with the disease based on clinical observations?
9. Does the use of tool compounds result in the same phenotype as, for instance, respective knockdown/knockout studies?

**Relevance of the model system**
10. Have healthy cells/tissues/animals been compared with diseased systems?
11. Can *in vitro* cell-based mechanistic studies be used to reveal characteristics of targets and the pathways in which they are involved?
12. For *in vivo* studies, does a functional connection exist between the animal model and humans?
13. Is extrapolation across species possible in order to select a relevant species?
14. Is the target functional in the preclinical species of choice?
15. Can human material be used to investigate the biology of the target?
16. If the target exists in multiple forms, do the expression levels of these variants vary across tissues and species?

**Target manipulation procedures**
17. Can the target-dependent effect be analysed in a bi-directional manner (e.g. rescuing the target knockout phenotype by re-expressing the protein of interest in target-deficient cells)?
18. Can highly selective target manipulation processes (e.g. KO technologies) be used rather than non-selectively induced changes in target?
19. Are knockout/knockdown studies complemented by small molecule or antibody studies that show the same phenotype?
20. Can the target be manipulated on a functional level rather than gene- or protein expression level?
21. Can naturally occurring target modification processes be analysed (e.g. gain-of-function or loss-of-function mutations)?
22. Does the target manipulation process lead to disease-affecting modifications?

**Readout**
23. Are readouts used therapeutically close to the clinical endpoint (e.g. a functional manifestation of disease, like muscle contraction)?
24. Can target-dependent processes be analysed on a system- or pathway-level, rather than gene- or protein-level?
25. Can disease-affecting modifications be analysed rather than symptomatic modifications?

**Stimulus**
26. Is the endogenous ligand/stimulus for the target and its concentration in the disease state known?
27. Can a biological system be used that intrinsically contains the appropriate disease-relevant stimulus?
28. Is the stimulation period justified by disease?
29. Target pathway: Does modulation of up- and downstream proteins lead to the same target-related phenotype?

**Effect sizes**

30. Is statistical significance treated as a criterion sufficient for decision making?
31. Can the therapeutic meaningfulness be treated as a criterion necessary for decision making?
Supplementary Box 2 | Experimental approach questions: target-related safety

**Reported evidence and prior knowledge**
1. Are any loss or gain-of-function mutations published in human and/or (preclinical) animal genetic databases?
2. Did any previous drug used to modify the target or a related pathway result in toxicity?
3. Do clinical study inclusion criteria provide any information on potential toxicities?
4. How unique is the target: are there conserved regions in homology of family and/or super-family members (e.g. are there redundancies)?
5. Could the modulation procedure interfere with other targets with similar sequence or other members of the target family?
6. Are there anticipated consequences of these off-target effects?

**Target expression/tissue distribution**
7. Is the target differentially expressed in samples representing the diseased state versus healthy controls?
8. Do the target distribution and expression patterns in humans and in the preclinical species differ?

**Tool compound use**
9. Does tool compound use lead to the same (toxic) phenotype compared to KO/KI animals?
10. How does the toxicity assessment of inactive enantiomers differ compared to active tool compounds?

**Pathway analysis and target function**
11. Is the target involved and plays a role in potentially harmful pathways and/or physiological processes?
12. If understanding of the target function is limited, can pathway up- or downstream components (or specific cellular functions related to the target) be analysed?

**Model system and translatability**
13. Are *in vitro* or pharmacologically relevant animal models available for safety testing?
14. Are the models to establish a link between target and disease of interest (see Target-Disease Linkage) and target-related safety models derived from the same species?
15. Is there a need to use transgenic animals for safety assessment?
16. Do transgenic KO/KI animals or target knockdown studies show adverse side-effects?
17. Species specificity: Are there differences in anatomy, physiology, target biology and/or expression distribution in sensitive species that may explain any species difference?

**Safety biomarker**
18. Can a cross-species, easily accessible, accurately measurable safety biomarker be identified or developed?
19. Can off-target binding/effects (detected by the biomarker) lead to potential toxicity?

**Safety window/risk–benefit ratio**
20. Can a significant therapeutic window between pharmacological effects and onset of toxicity be identified?
21. Which safety window may be acceptable for the desired indication or patient population?
22. Is the mechanism of toxicity known that is driving the safety margin evaluation?
23. Are safety biomarkers known that allow monitoring of safety risks as well as intervention (e.g. cessation of treatment, antidote)?
24. Is there a likely benefit for the patient population?
**Properties of the target and the microbial population**

1. Is the target essential for growth or survival of the organism under a chosen condition (Essentiality)?
2. Is the target amenable to chemical modulation (druggability)?
3. Is the target accessible to the inhibiting/modifying agent (accessibility)?
4. Is the target present in critical species (spectrum analysis)?
5. Do permeability and efflux properties of the microbial population of interest affect treatment options?

**Targeted gene modification and phenotype analysis**

6. Do target mutations result in a phenotypic change (e.g. loss of bacterial viability)?
7. What is the phenotype of modified strains upon target downregulation or overexpression (e.g. in the absence and presence of a tool compound)?
8. For an essential target, does a critical expression level threshold exist below which a particular phenotype (e.g. growth inhibition) will manifest?
9. Can the target vulnerability (defined as the degree of inhibition of the target’s function), which is required to significantly impact the cellular phenotype, be determined?

**Tool compounds**

10. For tool compound studies, can a variety of negative controls be included to show that the tested phenotypes are not caused by other classes of inhibitors not interfering with the target?
11. Can the risk of rapid resistance development be assessed with tool compounds?
12. Does antimicrobial activity track with enzyme-inhibitory potency?
13. If small molecule compounds are used as tool compounds, are they prone to chemical modification to optimize properties?

**Pathway analysis**

14. If one target enzyme is downregulated, does this affect another protein, e.g. in case both are part of the same pathway?
15. Pathway rescue: If a target is involved in a specific biosynthesis pathway, can the pathway end-product rescue a target-mutant phenotype?
16. For central metabolism pathways, how many pathways are available to the organism to synthesize a particular metabolite?
17. Can the organism scavenge the metabolite (or precursors) from the host?
18. Is the metabolite required throughout the course of infection, or only in certain disease states?

**Safety**

19. If there is a human homologue, can the microbial target be addressed specifically without interfering with the human counterpart?
20. If there is a human homologue, are there essential features in molecular structure, regulation or co-factor dependency that differentiate between them?
21. Can a significant therapeutic window between pharmacological effects and onset of toxicity be identified?
22. Are beneficial microbial populations (e.g. gut bacteria) affected by the antimicrobial treatment?

**Target location, expression and species specificity**

23. If the target is present only in specific species, does a tool compound show activity in only these species?
24. Is addressing only a single species sufficient cover for the intended therapeutic indication?
Resistance
25. Does the target of interest show mutations with high-fitness costs that prevent retention of resistance after removal of the selective pressure?
26. Does the target of interest show low potential for by-pass/compensatory mutations?
27. Does the target show low frequency of single-step and serial-passage mutations to resistance?

Method selection
28. Technical execution: Are current ‘state-of-the-art’ methods used or can the methods used be compared to the gold standard?
Supplementary Box 4 | Experimental approach questions: strategic issues

IP/patent situation
1. Can screening assay claims be used to protect newly developed target-related screening assays?
2. If the target can be modulated by RNAi and RNAi probes are known, can a patent be filed claiming the use of these probes against the target for the particular disease?
3. If the target can be modulated by an antibody, can a patent be filed claiming antibodies against the target?
4. Have antibodies (e.g. for humanization) been protected before use in any scientific publications?
5. Does the need to publish scientific results (including abstracts or public lectures) put any patent application at risk (and prohibit successful out-licensing)?
6. Defensive publication: If patenting is not possible, can ‘prior art’ be established by publishing a detailed description of the new target-related invention to prevent others from later being able to patent the invention?
7. Is the target modulation/compound screening approach unique in relation to existing IP?
8. Is it worthwhile to conduct a freedom to operate (FTO) analysis with regard to assays and reagents?
9. If patents by others exist, when were prior art references first published?

Unmet medical need
10. Do existing therapies have serious limitations with regard to efficacy or safety or both which may be overcome by the new approach?
11. Are the current treatment options disease modifying (or only symptomatic)?
12. Is the ratio between incidence of disease in a population and deaths in a population (because of a relevant disease) known?
13. Can biomarkers be developed for patient stratification (i.e. which patients would benefit from target modulation)?
14. Is the size, stratification and geographical distribution of the patient population known?
15. Are clinically relevant groups of patients identified?

Competitive landscape and differentiation
16. Is there a problem, inherent to the market, which would be solved by the new target-based product?
17. Are new compounds/biologics needed in addition to those discovered so far?
18. Is the new approach to modulate the target different to that used for existing medicines?
19. Is the target-based treatment approach novel (e.g. has a literature analysis been performed)?
20. Is there a rationale for target selection to drive differentiation over current standard of care?
21. Is the target of interest entirely new or have analogous targets been reported or patented?
22. What successes or failures have there been in the target area?
23. Is the new target-related treatment approach superior to the competitor’s product or method?

Commercial needs
24. Can a first hit/lead compound be developed to increase the commercial value of a data package?
25. Are costs needed to reach specific decision points (see TA Project Plan) defined and covered?
26. Are there potential additional indications in which the target might also play a role?
27. Do clinical data exist that are helpful when considering a new indication for a known target?
28. Can the future market size be estimated?
29. Does the target only play a role in rare diseases with small patient populations?
30. Can the reimbursement environment be assessed?
Supplementary Box 5 | **Experimental approach questions: technical feasibility**

**Accessibility**
1. Is the location of the target in its specific organ known?
2. Has the target location been taken into account when designing modulating compounds?
3. Do different forms or splice variants of the target influence cellular location or tissue distribution?
4. Should the target be blocked or activated? If target activation is required, can this be achieved?
5. Can a biological reaction be provoked as a consequence of a tool compound interacting with the target?

**Modifiability**
6. Is any bio-structural information available on the target?
7. Are 3D-structures available that enable the prediction of potential binding sites for small molecules (e.g. via structure-based druggability search engines)?
8. Are hit compounds/modulators already reported to modify the target?
9. Do different forms or splice variants of the target influence affinity for drug binding?
10. For target classes that have not been drugged before and/or are classified as difficult such as PPIs, can supporting structural data be obtained that demonstrate the druggability potential?

**Assayability**
11. Do meaningful surrogate endpoints exist that predict a clinical endpoint of interest?
12. Have methods already been reported for assaying the target?
13. If target splice variants exist in cells, are full-length proteins or catalytic domains more relevant for screening?
14. Is an orthogonal assay for HTS hit confirmation available to rule out assay artefacts?
15. Are secondary assays available with sufficient throughput to efficiently test the compounds from HTS?
16. What could be potential deselection assays and counter-screens (negative selection)?
17. Have the proposed discovery and orthogonal assays been tested with reference compounds and biological/genetic controls to confirm a link to target-mediated biological effects?
18. Is the assay pharmacologically predictive for the disease state?
19. Are assay reagents and volumes optimized with regard to costs required?
20. Is the Z factor of the assay greater than 0.4?
21. What final compound solvent concentrations can be tolerated or accepted?
22. Can a training set of compounds be screened to verify that the assay is performing acceptably?
23. Does the HTS meet standards for metrics such as robustness, efficiency and reproducibility?

**Tool compounds**
24. Can (in vivo) experiments be conducted to determine exposure-efficacy relationships?
25. If full target occupancy is confirmed for a tool modulator, does the tool modulator produce the expected therapeutic effect?
26. For tool antibodies: Can binding to the immunogen (e.g. via ELISA assays), cross-reactivity/specificity and potency be controlled?
27. For tool molecules: Can binding to the target in biophysical readouts, in biochemical assays and target engagement in cells be controlled?
28. Can target accessibility be analysed with available tool compounds?
29. Have structurally-related but inactive controls (e.g. inactive enantiomers) been used?
30. Have target mutagenesis studies to control for binding specificity been performed?
31. Has a selectivity profiling screen been performed for the tool compounds used?
32. Can the concentrations of compounds be measured inside cells to determine dose responses?
33. Does a selectivity window (on-target activity) for the tool compound exist?
34. Does the use of tool modulators result in the same phenotype as, for instance, respective knockdown/knockout studies?

35. If small molecule compounds are used as tool compounds, are they prone to chemical modification to optimize properties

**Target-related tolerance**

36. Is the target post-translationally modified?

37. What is the turnover rate of the target (i.e. the protein half-life in a cell)?

**Biomarker**

38. Are biomarkers available to monitor target modulation and/or target engagement?

39. If there is a cellular biomarker assay available, is the cellular readout compatible with *in vivo* target monitoring?

40. Is there a causal relationship between biomarker and disease (e.g. a biomarker as a disease component) or does the biomarker simply measure disease-related 'observations' without a key causal role (i.e. no impact on the disease outcome)?

41. Is there a correlative biomarker that can be monitored preclinically in the sensitive species that is clinically translatable?
Supplementary Box 6 | **Guiding questions related to documentation and traceability**

1. Are all notes taken directly after conducting the experiments?
2. Are all notes directly entered into the lab book?
3. Have lab notebooks been used in a structured way, e.g. by describing an experiment according to:
   a) Aim/goal /question
   b) Experimental procedure
   c) Description of results
   d) Discussion/interpretation
4. Are notes entered in chronological order?
5. Are study protocols complete and accessible?
6. Are all study outcomes documented and reported (both positive and negative results)?
7. Has the sample size been reported?
8. If several experiments overlap, can previous/subsequent parts of the protocol be identified by referring to respective page numbers?
9. If SOPs are used for the first time, are file name, version number and date added to the lab notebook?
10. If SOPs are permanently changed, are the new file name, version number, date documented in the lab notebook?
11. Are all deviations from standard protocols noted?
12. Are expectations, interpretations and observations distinguishable?
13. Are also minor observations noted, which can be important for subsequent interpretation of data sets?
14. Are empty pages/empty parts of pages crossed out in order to avoid later addition of information?
15. Are instrument/device settings and characteristics (e.g. manufacturer, model, or type ) noted?
16. Are order and lot numbers and the manufacturer of chemicals / media etc. noted?
17. Have all entries been approved, signed and dated?
18. Are electronic records in compliance with FDA’s 21 CFR Part 11?
19. Can a witnessing process be implemented?
20. Are all (raw) data sets traceable (related to storage, retrieval and reconstruction of data) and reusable?
Supplementary Box 7 | Examples highlighting the importance of various target assessment aspects

Target–disease linkage (relevance of the model system)
Establishing a clear link between target and disease can be challenging if no adequate preclinical model systems exist. Often, the target environment in a complex human setting is modelled by animal systems reflecting and focusing only on individual aspects or factors influencing the target of interest. One example is the protein kinase C (PKC) enzyme family, which has been extensively studied as a target in various disease models and has been linked to cardiovascular disease and cancer. It proved difficult to translate the elaborate findings to new drugs, in part because the mice models were not ideally simulating the human system and the PKC isoforms are too tightly regulated and fine-balanced. This shows that a more robust understanding of the underlying biology and comparison of pathways identified in human specimens and the development of relevant in vivo models is essential for therapeutic progress in this field2–4.

Target–disease linkage (establishing causality)
The ‘amyloid hypothesis’ initially postulated that the accumulation and deposition of amyloid β (Aβ) peptide is causally related to development and progression of Alzheimer’s disease (AD)5–7. Several treatments have successfully been shown to reduce the Aβ plaque load, but without any positive therapeutic impact. Causality claims have been based exclusively on transgenic mouse models with overexpression of APP triggering a variety of impairments but, notably, no neuronal loss or neurofibrillary tangles, which are also hallmarks of Alzheimer’s disease8.

These findings demonstrate the relevance of the GOT-IT CPQ #1 “Is the target perturbation a cause or consequence of the human disease process?” and the importance of rejecting the null hypothesis that the selected target of interest is not causally linked to the disease of interest as early as possible to save time and resources.

Early safety de-risking of a novel target example 1
In approaches targeting novel cancer/testis tumour-associated antigens (TAAs), target-related toxicity is a concern due to unrecognized expression of some cancer/testis antigens on rare vital cells (e.g. in the brain). In this context, however, studies addressing GOT-IT CPQ #15 “Is the tissue distribution of the target known?” generated new data on tissue distribution of the targets in question, such as MAGE A1, and could decrease the risk of occurrence of unsolicited side effects, demonstrating the importance of understanding target expression and distribution levels9.

Early safety de-risking of a novel target example 2
In 1999, an evaluation of 150 compounds from 12 pharmaceutical companies showed that of a total of 221 human toxicities identified, the proportion of target-related toxicities (versus off-target toxicity) in clinical trials was 35% in Phase I, 39% in Phase II and 43% in Phase III10. A later analysis by AstraZeneca of their 2005–2010 portfolio found that project closures due to safety were 82% preclinically, 62% in Phase I, 35% in Phase IIa and 12% in Phase IIb. In the AstraZeneca review, the ratio between target- and compound-related toxicity was 25% versus 75% for preclinical failures and 48% versus 52% for clinical failures11. The results of this analysis led to early hypothesis testing for target-related safety risks at AstraZeneca12, in line with the strategy of other pharmaceutical companies13.

Tool compound use
Many tool compounds are not fully characterized or have outdated specificity profiles, yet are still frequently used, leading to incorrect conclusions14.

Prominent examples are dorsomorphin, a chemical probe that was originally advertised and used as a TGF-beta receptor kinase inhibitor as well as a nanomolar inhibitor of AMPK signalling. However, it has been shown that at least 10 other kinases are more potently inhibited by
dorsomorphin compared to AMPK or TGF-beta kinase, questioning the value of the results obtained using this tool compound\textsuperscript{15}.

Similarly, the chemical probe LY294002 was developed in 1994 and advertised as a selective PI3 kinase inhibitor. However, it became apparent in the following years that LY294002 also affects many other proteins at the concentrations used to inhibit PI3 kinase and that more specific and higher-quality probes are available. LY294002, though, is still widely used and published in scientific literature in the context of PI3 kinase research\textsuperscript{16}.

**Target engagement biomarker use and development**

Corticotropin-releasing factor receptor 1 (CRF1) has been implicated in behavioural and cognitive responses to stress and preclinical studies predict the use of CRF1 receptor antagonists as possible treatments for depression and alcohol use disorders. Several studies have suggested the central role of CRF1 receptors\textsuperscript{17-19}. However, clinical translation of these preclinical results has not yet been achieved. One reason for this may be the unavailability of a CRF1 biomarker (e.g. radiotracer for PET/SPECT imaging) to confirm adequate target engagement in humans\textsuperscript{20,21}.

Applying the GOT-IT framework would have identified the need for early development of target engagement biomarkers for projects focusing on CRF1 (CPQ #32 “Are biomarkers available to demonstrate target engagement in patients?”), which would have helped to optimize prioritization of drug candidates and dosing. Thus, the development of e.g. CRF1 PET radioligands will further validate CRF1 as a suitable drug target by controlling receptor occupancy.

**Target assayability example 1**

G protein-coupled receptors (GPCRs) are an important family of drug targets. Most widely used GPCR assays for compound screening focus on receptor–ligand binding or the functional analysis of downstream signalling events. However, the majority of GPCRs in the brain are orphan receptors, whose endogenous ligands and downstream signalling are unknown. Consequently, orphan GPCRs are underexploited for drug discovery due to the lack of appropriate technologies for compound library screening, despite the fact that the druggability of this target class is unquestionable. Thus, whereas screening assays can usually readily be established for de-orphaned GPCR targets, in contrast, orphan GPCRs will probably yield less favourable assay outcomes\textsuperscript{22,23}.

Applying the GOT-IT framework (CPQ #31 “Can the target be assayed in a relevant system?”) would help to identify this potential roadblock for further drug discovery and would re-direct resources to finding alternative solutions like receptor-internalization assays, which do not require prior knowledge of G protein coupling conditions and signalling pathways of the receptor\textsuperscript{24-26}.

**Target assayability example 2**

In a project to identify novel, non-peptide bradykinin receptor antagonists, a receptor binding assay was set up using the guinea-pig ileum and muscarinic receptor binding, as a control for specificity, was assessed in rat brain. A hit compound acted at both receptors, so a low affinity at the bradykinin receptor was sought in a screen of novel structural derivatives. Further testing on fibroblasts of compounds with higher affinity revealed that they were not acting via bradykinin receptors but by inhibiting prostaglandin synthesis. The best compound NPC 12957 had a $K_i$ for bradykinin receptors of 400 nM and had no effect on muscarinic receptors, but was non-specific in functional assays and the chemical class was abandoned. However, starting with a different chemical scaffold, binding affinity with a $K_i$ of 200 pM could be achieved and these compounds were highly specific for bradykinin receptors\textsuperscript{27}. This example shows the importance of establishing a target screening assay with carefully defined criteria to identify potent, specific modulators and to answer the GOT-IT framework CPQ #31 “Can the target be assayed in a relevant system?”.
**Antibacterial aspects example 1 (resistance development)**

Drug efflux pumps can play a key role in drug resistance. This aspect is addressed by the GOT-IT EAQ #5 (Supplementary Box 3) “Do permeability and efflux properties of the microbial population of interest affect treatment options?” The expression of drug pumps is often subjected to induction by small molecules like antibacterials, which can interact with regulatory systems. For example, pumps specific for the common natural product tetracycline (TET), of which 30 are known, possess regulatory controls that sense the presence of the antibiotic and TET therefore acts as an ‘inducer’, leading to an increased efflux pump expression level and consequently drug resistance development\(^2\). This limits the use of these drugs to sensitive bacterial strains. Tigecycline, a relatively new tetracycline, was developed taking this issue into account and is much less active as a substrate for efflux pumps, exerting a broad spectrum of activity against resistant bacterial strains\(^2\).

**Antibacterial aspects example 2 (target validation in vitro versus in vivo)**

The need to evaluate target essentiality not only *in vitro* but also *in vivo* is addressed, amongst others, by the GOT-IT guiding question EAQ #17 (Supplementary Box 3) “Can the organism scavenge the metabolite (or precursors) from the host?”. Answering this question identified a major roadblock when several pharma companies investigated fatty acid biosynthesis pathway as a potential target pathway. After having identified multiple leads and drug candidates, it was found that important Gram-positive pathogens are resistant to fatty acid biosynthesis inhibitors *in vitro*, when supplied with exogenous fatty acids in a concentration present in human serum or when human serum is added\(^3\). Thus, these results challenge and compromise the development of antimicrobials targeting the fatty acid synthesis pathway used by Gram-positive pathogens, by considering the therapeutically relevant infection conditions.
Supplementary Box 8 | Details and methods for the literature analysis presented in Box 1

Protocol for database search
The search was performed using the PubMed Advance Search Builder of the PubMed Database at the US National Center for Biotechnology Information. It was delimited in time using the operator AND and the publication dates 2010/01/01 to 2018/04/30. It was specified that the publication types ‘Review’ and ‘Clinical trial’ were not to be included in the search.

A total of 6 different searches were performed, one for each of the following indications: Cancer, Diabetes, Cardiology, Neurology, Immunology, Infectious Diseases. For this, the search terms were defined and connected as follows: (novel OR new) AND (target OR agent OR therapy OR therapeutic OR treatment) AND (association OR associated OR relevance OR link OR related OR relation) AND (validate OR validation OR validated OR validating) AND (XXX), where XXX denotes indication specific search terms. These were: (solid tumor OR leukemia) for Cancer; (diabetes) for Diabetes; (cardiovascular *NOT (All Fields) Diabetic or diabetes) for Cardiology; (neurology OR neurobiology) for Neurology; (innate immun* OR adaptive immun* OR autoimmun*) for Immunology; and (antibiotic OR antiviral OR bacteria OR virus) for Infectious Diseases. Finally, results were displayed according to the BEST MATCH option.

Inclusion and exclusion criteria
In order to be selected for analysis, publications had to meet the following inclusion criteria: 1) describe validation procedures of a gene, a protein, a pathway or a molecule previously identified as a potential therapeutic target of a human disease; 2) be written in scientific English; 3) be published by academic research groups.

Excluded from analysis were publications with the following characteristics: 1) Review or clinical trial articles, as well as commentaries, editorials, letters, and similar; 2) Publications from industrial research groups; 3) Publications dealing exclusively with: validation of biomarkers for diagnostic and/or prognostic assays; genetic screening, microarray analysis/screening; papers related to expanding patient lifespan and patient quality of life; bioinformatic analysis (without presenting experimental research data); 4) Articles whose abstracts were not available via PubMed; and 5) Articles failing to meet the inclusion criteria.

Number of papers selected
Following the primary search based on the selected search terms, 3307 relevant abstracts were identified (see figure below). After reviewing of titles and abstracts by two independent reviewers (in case of discordance, a third independent reviewer classified the article as relevant or non-relevant), 2743 were excluded (due to specified exclusion criteria or failure to meet inclusion criteria). The 564 relevant publications were retrieved as full-text papers for detailed analysis.

Following the review of these papers, further 136 papers were excluded, leaving a total of 428 papers that were included in the final literature analyses (162 for cancer, 56 for cardiology, 63 for diabetes, 26 for immunology, 68 for neurobiology and 53 for infectious diseases). A full list of all 428 articles is provided below.
Figure | Literature analysis. Overview of all retrieved, excluded and selected articles for analysis of aspects related to Target Assessment in Academia.

Review of full-text publications
Full-text articles were sorted according to indication and analysed for the presence or absence of each of the pre-defined TA elements or data quality standards. The selection and definition of TA elements was based on the Validation Block categories (see main article). The percentage of papers which have discussed, used or implemented one or more of each TA element or Landis 4 criteria, respectively, was calculated and presented in Box 1.

Potential limitations of the analysis
This analysis is based on information extracted from publications. Regarding the implementation of measures taken to avoid bias (reporting of randomisation, the blinded assessment of outcome, sample size calculations and whether samples or animals were excluded from analysis), it is possible that some poorly reported studies are in fact well-designed and well-conducted, but failed to describe measures taken.

References
1. Wyatt, P. G., Gilbert, I. H., Read, K. D. & Fairlamb, A. H. Target validation: linking target and chemical properties to desired product profile. Curr. Top. Med. Chem. 11, 1275–1283 (2011).
2. Mochly-Rosen, D., Das, K. & Grimes, K. V. Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 11, 937–957 (2012).
3. Newton, A. C. & Brognard, J. Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends Pharmacol. Sci. 38, 438–447 (2017).
4. Isakov, N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin. Cancer Biol. 48, 36–52 (2018).
5. Hardy, J. & Selkoe, D. J. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science 297, 353–356 (2002).
6. Blessed, G., Tomlinson, B. E. & Roth, M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry J. Ment. Sci. 114, 797–811 (1968).
7. Roth, M., Tomlinson, B. E. & Blessed, G. Correlation between Scores for Dementia and Counts of ‘Senile Plaques’ in Cerebral Grey Matter of Elderly Subjects. *Nature* **209**, 109–110 (1966).
8. Kim, J. *et al.* Normal cognition in transgenic BRI2-ABβ mice. *Mol. Neurodegener.* **8**, 15 (2013).
9. Obenau, M. *et al.* Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. *Nat. Biotechnol.* **33**, 402–407 (2015).
10. Olson, H. *et al.* Concordance of the toxicity of pharmaceuticals in humans and in animals. *Regul. Toxicol. Pharmacol. RTP* **32**, 56–67 (2000).
11. Cook, D. *et al.* Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. *Nat. Rev. Drug Discov.* **13**, 419–431 (2014).
12. Morgan, P. *et al.* Impact of a five-dimensional framework on R&D productivity at AstraZeneca. *Nat. Rev. Drug Discov.* **17**, 167–181 (2018).
13. Hornberg, J. J. *et al.* Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. *Drug Discov. Today* **19**, 1131–1136 (2014).
14. Arrowsmith, C. H. *et al.* The promise and peril of chemical probes. *Nat. Chem. Biol.* **11**, 536–541 (2015).
15. Vogt, J., Traynor, R. & Sapkota, G. P. The specificities of small molecule inhibitors of the TGFβ and BMP pathways. *Cell. Signal.* **23**, 1831–1842 (2011).
16. Workman, P., Clarke, P. A., Raynaud, F. I. & van Montfort, R. L. M. Drugging the PI3 kinase: from chemical tools to drugs in the clinic. *Cancer Res.* **70**, 2146–2157 (2010).
17. Quadros, I. M. H., Macedo, G. C., Domingues, L. P. & Favoretto, C. A. An Update on CRF Mechanisms Underlying Alcohol Use Disorders and Dependence. *Front. Endocrinol.* **7**, (2016).
18. Pomrenze, M. B., Fetterly, T. L., Winder, D. G. & Messing, R. O. The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? *Alcohol. Clin. Exp. Res.* **41**, 1986–1999 (2017).
19. Kehne, J. H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. *CNS Neurol. Disord. Drug Targets* **6**, 163–182 (2007).
20. Schwandt, M. L. *et al.* The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Antidepressant, Effects. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **41**, 2818–2829 (2016).
21. Spierling, S. R. & Zorrilla, E. P. Don’t stress about CRF: assessing the translational failures of CRF1 antagonists. *Psychopharmacology (Berl.)* **234**, 1467–1481 (2017).
22. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. *Nat. Rev. Drug Discov.* **16**, 829–842 (2017).
23. Zhang, R. & Xie, X. Tools for GPCR drug discovery. *Acta Pharmacol. Sin.* **33**, 372–384 (2012).
24. Hirasawa, A. *et al.* Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. *Nat. Med.* **11**, 90–94 (2005).
25. Hansen, K. B. & Bräuner-Osborne, H. FLIPR assays of intracellular calcium in GPCR drug discovery. *Methods Mol. Biol. Clifton NJ* **552**, 269–278 (2009).
26. Salahpour, A. & Barak, L. S. Visualizing Receptor Endocytosis and Trafficking. in *Signal Transduction Protocols* (eds. Luttrell, L. M. & Ferguson, S. S. G.) 311–323 (Humana Press, 2011). doi:10.1007/978-1-61779-160-4_18
27. Burch, R. M. & Kyle, D. J. Mass Receptor Screening for New Drugs. *Pharm. Res.* **8**, 141–147 (1991).
28. Li, X.-Z. & Nikaido, H. Efflux-Mediated Drug Resistance in Bacteria: an Update. *Drugs* **69**, 1555–1623 (2009).
29. Grossman, T. H. Tetracycline Antibiotics and Resistance. *Cold Spring Harb. Perspect. Med.* **6**, a025387 (2016).
30. Brinster, S. *et al.* Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. *Nature* **458**, 83–86 (2009).
31. Moher, D. *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* **4**, 1 (2015).
32. Landis, S. C. *et al.* A call for transparent reporting to optimize the predictive value of preclinical research. *Nature* **490**, 187–191 (2012).
List of 428 articles included in the final literature analysis

Abate, F.; Todaro, M.; van der Krogt, J-A; Boi, M.; Landra, I.; Machiorlatti, R. et al. (2015): A novel patient-derived tumourgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. In Leukemia 29 (6), pp. 1390–1401. DOI: 10.1038/leu.2014.347.

Abdallah, Cosette; Lejamtel, Charlène; Benzoubir, Nassima; Battaglia, Serena; Sidahmed-Adrar, Nazha; Desterke, Christophe et al. (2017): Hepatitis C virus core protein targets 4E-BP1 expression and phosphorylation and potentiates Myc-induced liver carcinogenesis in transgenic mice. In Oncotarget 8 (34), pp. 56228–56242. DOI: 10.18632/oncotarget.17280.

Abulwerdi, Fardokht; Liao, Chenzhong; Liu, Meilan; Azmi, Asfar S.; Aboukameel, Amro; Mady, Ahmed S. A. et al. (2014): A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. In Molecular cancer therapeutics 13 (3), pp. 565–575. DOI: 10.1158/1535-7163.MCT-12-0767.

Abulwerdi, Fardokht A.; Liao, Chenzhong; Mady, Ahmed S.; Gavin, Jordan; Shen, Chenxi; Cierpicki, Tomasz et al. (2014): 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. In Journal of medicinal chemistry 57 (10), pp. 4111–4133. DOI: 10.1021/jm500010b.

Agnihotri, Sameer; Jalali, Shahrzad; Wilson, Mark R.; Danesh, Arnavaz; Husain, Sanam; Gillaspy, Allison F.; Huycke, Mark et al. (2015): Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. In Oncotarget 6 (24), pp. 20327–20344. DOI: 10.18632/oncotarget.3972.

Alinari, Lapo; Mahasenan, Kiran V.; Yan, Fengtong; Karkhanis, Vrajesh; Chung, Ji-Hyun; Smith, Emily M. et al. (2015): Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. In Blood 125 (16), pp. 2530–2543. DOI: 10.1182/blood-2014-12-619783.

Amin, Nisar A.; Balasubramanian, Sriram; Saiya-Cork, Kamlai; Shedden, Kerby; Hu, Nan; Malek, Sami N. (2017): Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. In Clinical cancer research : an official journal of the American Association for Cancer Research 23 (4), pp. 1049–1059. DOI: 10.1158/1078-0432.CCR-15-2921.

Anunziato, Giannamaria; Angeli, Andrea; D'Alba, Francesca; Bruno, Agostino; Pieroni, Marco; Vullo, Daniela et al. (2016): Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches. In ChemMedChem 11 (17), pp. 1904–1914. DOI: 10.1002/cmdc.201600180.

Apps, John R.; Carreno, Gabriela; Gonzalez-Mejlej, Jose Mario; Haston, Scott; Guiho, Romain; Cooper, Julie E. et al. (2018): Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. In Acta neuropathologica 135 (5), pp. 757–777. DOI: 10.1007/s00401-018-1830-2.

Aruleba, Raphael Taiwo; Adekiya, Tayo Alex; Oyinloye, Babatunji Emmanuel; Kappo, Abidemi Paul (2018): Structural Studies of Predicted Ligand Binding Sites and Molecular Docking Analysis of Slc2a4...
as a Therapeutic Target for the Treatment of Cancer. In International journal of molecular sciences 19 (2). DOI: 10.3390/ijms19020386.

Asaduzzaman, Muhammad; Constantinou, Stephanie; Min, Haoxiang; Gallon, John; Lin, Meng-Lay; Singh, Poonam et al. (2017): Tumour suppressor EP300, a modulator of paclitaxel resistance and tumour stemness, is downregulated in metaplastic breast cancer. In Breast cancer research and treatment 163 (3), pp. 461–474. DOI: 10.1007/s10549-017-4202-z.

Bachegowda, Lohith; Morrone, Kerry; Winski, Shannon L.; Mantzaris, Ioannis; Bartenstein, Matthias; Ramachandra, Nandini et al. (2016): Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. In Cancer research 76 (16), pp. 4841–4849. DOI: 10.1158/0008-5472.CAN-15-3062.

Bai, Alfa H. C.; Wu, William K. K.; Xu, Liangliang; Wong, Sunny H.; Go, Minnie Y.; Chan, Anthony W. H. et al. (2016): Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10. In Journal of Crohn’s & colitis 10 (6), pp. 726–734. DOI: 10.1093/ecco-jcc/jjw020.

Bala, Manju; Pratap, Kunal; Verma, Praveen Kumar; Singh, Bikram; Padwad, Yogendra (2015): Validation of ethnomedicinal potential of Tinospora cordifolia for anticancer and immunomodulatory activities and quantification of bioactive molecules by HPTLC. In Journal of ethnopharmacology 175, pp. 131–137. DOI: 10.1016/j.jep.2015.08.001.
Bastian, Lorenz; Hof, Jana; Pfau, Madlen; Fichtner, Iduna; Eckert, Cornelia; Henze, Günter et al. (2013): Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kB. In Clinical cancer research : an official journal of the American Association for Cancer Research 19 (6), pp. 1445–1457. DOI: 10.1158/1078-0432.CCR-12-1511.

Bauer, Robert C.; Tohyama, Junichiro; Cui, Jian; Cheng, Lan; Yang, Jifu; Zhang, Xuan et al. (2015): Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. In Circulation 131 (13), pp. 1202–1213. DOI: 10.1161/CIRCULATIONAHA.114.012669.

Beck, Tim N.; Georgopoulos, Rachel; Shagisultanova, Elena I.; Sarcu, David; Handorf, Elizabeth A.; Dubyk, Cara et al. (2016): EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. In Molecular cancer therapeutics 15 (10), pp. 2486–2497. DOI: 10.1158/1535-7163.MCT-16-0243.

Bernatchez, Jean A.; Paul, Rakesh; Tchesnokov, Egor P.; Ngure, Marianne; Beilhartz, Greg L.; Berghuis, Albert M. et al. (2015): Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase. In The Journal of biological chemistry 290 (3), pp. 1474–1484. DOI: 10.1074/jbc.M114.614305.

Bhoopathi, Praveen; Lee, Nathaniel; Pradhan, Anjan K.; Shen, Xue-Ning; Das, Swadesh K.; Sarkar, Devanand et al. (2016): mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM. In Cancer research 76 (12), pp. 3572–3582. DOI: 10.1158/0008-5472.CAN-15-2959.

Bhutra, Steven; Lenkala, Divya; LaCroix, Bonnie; Ye, Meng; Huang, R. Stephanie (2014): Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. In PloS one 9 (12), e115003. DOI: 10.1371/journal.pone.0115003.

Blanco, Mario Andres; LeRoy, Gary; Khan, Zia; Alečković, Maša; Zee, Barry M.; Garcia, Benjamin A.; Kang, Yibin (2012): Global secretome analysis identifies novel mediators of bone metastasis. In Cell research 22 (9), pp. 1339–1355. DOI: 10.1038/cr.2012.89.

Blohmkke, Christoph J.; Park, Julie; Hirschfeld, Aaron F.; Victor, Rachel E.; Schneiderman, Julia; Stefanowicz, Dorota et al. (2010): TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. In Journal of immunology (Baltimore, Md. : 1950) 185 (12), pp. 7731–7738. DOI: 10.4049/jimmunol.1001513.

Bockorny, Bruno; Rusan, Maria; Chen, Wankun; Liao, Rachel G.; Li, Yvonne; Piccioni, Federica et al. (2018): RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. In Molecular cancer therapeutics 17 (7), pp. 1526–1539. DOI: 10.1158/1535-7163.MCT-17-0464.

Boldrin, Francesca; Ventura, Marcello; Degiacomi, Giulia; Ravishankar, Sudha; Sala, Claudia; Svetlikova, Zuzana et al. (2014): The phosphatidyl-myoinositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. In Journal of bacteriology 196 (19), pp. 3441–3451. DOI: 10.1128/JB.01346-13.

Bugeye-Twum, Antoinette; Advani, Andrew; Advani, Suzanne L.; Zhang, Yuan; Thai, Kerri; Kelly, Darren J.; Connelly, Kim A. (2014): High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. In Cardiovascular diabetology 13, p. 89. DOI: 10.1186/1475-2840-13-89.

Burgess, Michael R.; Hwang, Eugene; Firestone, Ari J.; Huang, Tannie; Xu, Jin; Zuber, Johannes et al. (2014): Preclinical efficacy of MEK inhibition in Nras-mutant AML. In Blood 124 (26), pp. 3947–3955. DOI: 10.1182/blood-2014-05-574582.
Burgoyne, Joseph R.; Prsyazhna, Oleksandra; Richards, Daniel A.; Eaton, Philip (2017): Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG Iα (Protein Kinase G Iα). In Hypertension (Dallas, Tex. : 1979) 70 (3), pp. 577–586. DOI: 10.1161/HYPERTENSIONAHA.117.09670.

Burillo, Elena; Tarin, Carlos; Torres-Fonseca, Monica-Maria; Fernandez-García, Carlos-Ernesto; Martinez-Pinna, Roxana; Martinez-Lopez, Diego et al. (2016): Paraoxonase-1 overexpression prevents experimental abdominal aortic aneurysm progression. In Clinical science (London, England : 1979) 130 (12), pp. 1027–1038. DOI: 10.1042/CS20160185.

Cabezas-Wallscheid, Nina; Eichwald, Victoria; Graaf, Jos de; Löwer, Martin; Lehr, Hans-Anton; Kreft, Andreas et al. (2013): Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. In EMBO molecular medicine 5 (12), pp. 1804–1820. DOI: 10.1002/emmm.201302661.

Cai, Baowei; Wu, Jian; Yu, Xiao; Su, Xin-Zhuan; Wang, Rong-Fu (2017): FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions. In mBio 8 (1). DOI: 10.1128/mBio.02161-16.

Campbell, Susan L.; Robel, Stefanie; Cuddapah, Vishnu A.; Robert, Stephanie; Buckingham, Susan C.; Kahle, Kristopher T.; Sontheimer, Harald (2015): GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. In Glia 63 (1), pp. 23–36. DOI: 10.1002/glia.22730.

Capauto, Davide; Colantoni, Alessio; Lu, Lei; Santini, Tiziana; Peruzzi, Giovanna; Biscarini, Silvia et al. (2018): A Regulatory Circuitry Between Gria2, miR-409, and miR-495 Is Affected by ALS FUS Mutation in ESC-Derived Motor Neurons. In Molecular neurobiology 55 (10), pp. 7635–7651. DOI: 10.1007/s12035-018-0884-4.

Cermáková, Kateřina; Tesina, Petr; Demeulemeester, Jonas; El Ashkar, Sara; Méreau, Hélène; Schwaller, Juerg et al. (2014): Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. In Cancer research 74 (18), pp. 5139–5151. DOI: 10.1158/0008-5472.CAN-13-3602.

Chaliha, Amrita Kashyap; Gogoï, Dhrubajyoti; Chetia, Pankaj; Sarma, Diganta; Buragohain, Alak Kumar (2016): An In Silico Approach for Identification of Potential Anti-Mycobacterial Targets of Vascine and Related Chemical Compounds. In Combinatorial chemistry & high throughput screening 19 (1), pp. 14–24. DOI: 10.2174/1386207319666151203001708.

Challita-Eid, Pia M.; Satpayev, Daulet; Yang, Peng; An, Zili; Morrison, Karen; Shostak, Yuriy et al. (2016): Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. In Cancer research 76 (10), pp. 3003–3013. DOI: 10.1158/0008-5472.CAN-15-1313.

Chang, Hung-Chi; Yang, Su-Fu; Huang, Ching-Chun; Lin, Tzung-Sheng; Liang, Pi-Hui; Lin, Chun-Jung; Hsu, Lih-Ching (2013): Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG. In Molecular bioSystems 9 (8), pp. 2010–2020. DOI: 10.1039/c3mb70060g.

Chao, Jie; Yang, Lu; Yao, Honghong; Buch, Shilpa (2014): Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis: role of GSK-3β/β-catenin. In Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 9 (2), pp. 259–268. DOI: 10.1007/s11481-013-9509-x.

Chen, Deyu; Mao, Chaoming; Zhou, Yuepeng; Su, Yuting; Liu, Shenzha; Qi, Wen-Qing (2016): PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1
cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. In International journal of oncology 48 (1), pp. 253–260. DOI: 10.3892/ijo.2015.3231.

Chen, Fei-Fei; Wang, Jian-Ta; Zhang, Li-Xia; Xing, Shu-Fang; Wang, Yun-Xia; Wang, Kai et al. (2017): Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells. In British journal of pharmacology 174 (17), pp. 2912–2928. DOI: 10.1111/bph.13921.

Chen, Min; Turhan, Ali G.; Ding, Hongxia; Lin, Qingcong; Meng, Kun; Jiang, Xiaoyan (2017): Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. In Oncotarget 8 (27), pp. 43662–43677. DOI: 10.18632/oncotarget.18216.

Chen, Xiulan; Wei, Shasha; Ma, Ying; Lu, Jie; Niu, Gang; Xue, Yanhong et al. (2014): Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. In Theranostics 4 (12), pp. 1164–1175. DOI: 10.7150/thno.8502.

Chen, Yong; Min, Lingfeng; Ren, Chuanli; Xu, Xingxiang; Yang, Jianqi; Sun, Xinchen et al. (2017): miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. In PloS one 12 (2), e0171751. DOI: 10.1371/journal.pone.0171751.

Chen, Haiying; Janakiram, Murali; Borczuk, Alain; Lin, Juan; Qiu, Wanglong; Liu, Huijie et al. (2017): HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. In Clinical cancer research : an official journal of the American Association for Cancer Research 23 (3), pp. 825–832. DOI: 10.1158/1078-0432.CCR-15-3071.

Chivero, Ernest T.; Guo, Ming-Lei; Periyasamy, Palsamy; Liao, Ke; Callen, Shannon E.; Buch, Shilpa (2017): HIV-1 Tat Primes and Activates Microglial NLRP3 Inflammasome-Mediated Neuroinflammation. In The Journal of neuroscience : the official journal of the Society for Neuroscience 37 (13), pp. 3599–3609. DOI: 10.1523/JNEUROSCI.3045-16.2017.

Cho, Newton; Nguyen, Dung H.; Satkunendararajah, Kajana; Branch, Donald R.; Fehlings, Michael G. (2012): Evaluating the role of IL-11, a novel cytokine in the IL-6 family, in a mouse model of spinal cord injury. In Journal of neuroinflammation 9, p. 134. DOI: 10.1186/1742-2094-9-134.

Choe, Chi-un; Atzler, Dorothee; Wild, Philipp S.; Carter, Angela M.; Böger, Rainer H.; Ojeda, Francisco et al. (2013): Homoarginine levels are regulated by L-arginine:glycine amidinotransferase and affect stroke outcome: results from human and murine studies. In Circulation 128 (13), pp. 1451–1461. DOI: 10.1161/CIRCULATIONAHA.112.000580.

Collin, Roxanne; Dugas, Véronique; Pelletier, Adam-Nicolas; Chabot-Roy, Geneviève; Lesage, Sylvie (2014): The mouse idd2 locus is linked to the proportion of immunoregulatory double-negative T cells, a trait associated with autoimmune diabetes resistance. In Journal of immunology (Baltimore, Md. : 1950) 193 (7), pp. 3503–3512. DOI: 10.4049/jimmunol.1400189.

Conti, Valerio; Aracri, Patrizia; Chiti, Laura; Brusco, Simone; Mari, Francesco; Marini, Carla et al. (2015): Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function. In Neurology 84 (15), pp. 1520–1528. DOI: 10.1212/WNL.0000000000001471.
Correia, Catarina T.; Conceição, Inês C.; Oliveira, Bárbara; Coelho, Joana; Sousa, Inês; Sequeira, Ana F. et al. (2014): Recurrent duplications of the annexin A1 gene (ANXA1) in autism spectrum disorders. In Molecular autism 5 (1), p. 28. DOI: 10.1186/2040-2392-5-28.

Cousin, Margot A.; Zimmermann, Michael T.; Mathison, Angela J.; Blackburn, Patrick R.; Boczek, Nicole J.; Oliver, Gavin R. et al. (2017): Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loey-Dietz syndrome (LDS) impairs canonical TGF-β signaling. In Cold Spring Harbor molecular case studies 3 (4). DOI: 10.1101/mcs.a001727.

Cowan, Colleen; Muraleedharan, Chithra K.; O’Donnell, James J.; Singh, Pawan K.; Lum, Hazel; Kumar, Ashok; Xu, Shunbin (2014): MicroRNA-146 inhibits thrombin-induced inflammatory responses in human retinal endothelial cells. In Investigative ophthalmology & visual science 55 (8), pp. 4944–4951. DOI: 10.1167/iovs.13-13631.

Crouthamel, Matthew H.; Wu, Daniel; Yang, Ziping; Ho, Rodney J. Y. (2010): A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions. In The AAPS journal 12 (4), pp. 548–555. DOI: 10.1208/s12248-010-9216-y.

Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Sánchez-Arias, Juan A.; Rabal, Obdulia; Pérez-González, Marta; Mederos, Sara et al. (2017): A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice. In Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 42 (2), pp. 524–539. DOI: 10.1038/npp.2016.163.

Cuadros, M.; Sánchez-Martín, V.; Herrero, A.; Bialiñas, C.; Martín-Padrón, J.; Boyero, L. et al. (2017): BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. In Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 19 (8), pp. 1010–1017. DOI: 10.1007/s12094-017-1633-2.

Dahlmans, Dennis; Houzelle, Alexandre; Andreux, Pénélope; Jorgensen, Johanna A.; Wang, Xu; Windt, Leon J. de et al. (2017): An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism. In Molecular metabolism 6 (11), pp. 1429–1442. DOI: 10.1016/j.molmet.2017.08.007.

Dai, Lu; Cao, Yueyu; Chen, Yihan; Kaleeba, Johnan A. R.; Zabaleta, Jovanny; Qin, Zhiqiang (2015): Genomic analysis of xCT-mediated regulatory network: Identification of novel targets against AIDS-associated lymphoma. In Oncotarget 6 (14), pp. 12710–12722. DOI: 10.18632/oncotarget.3710.

Dai, Wenjian; He, Weiqing; Shang, Guangdong; Jiang, Jiandong; Wang, Yiguang; Kong, Weijia (2010): Gene silencing of myofibrillogenesis regulator-1 by adenovirus-delivered small interfering RNA suppresses cardiac hypertrophy induced by angiotensin II in mice. In American journal of physiology. Heart and circulatory physiology 299 (5), H1468-75. DOI: 10.1152/ajpheart.00582.2009.

Damiani, Verena; Falvo, Elisabetta; Fracasso, Giulio; Federici, Luca; Pitea, Martina; Laurenzi, Vincenzo de et al. (2017): Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model. In International journal of molecular sciences 18 (7). DOI: 10.3390/ijms18071555.

D’Arcy, Pádraig; Brnjic, Slavica; Olofsson, Maria Hägg; Fryknäs, Mårten; Lindsten, Kristina; Cesare, Michelandrea de et al. (2011): Inhibition of proteasome deubiquitinating activity as a new cancer therapy. In Nature medicine 17 (12), pp. 1636–1640. DOI: 10.1038/nm.2536.

Davies, Carwyn; Hogarth, Linda A.; Dietrich, Philipp A.; Bachmann, Petra S.; Mackenzie, Karen L.; Hall, Andrew G.; Lock, Richard B. (2011): p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. In The Journal of biological chemistry 286 (43), pp. 37639–37650. DOI: 10.1074/jbc.M111.272336.
Deckert, Jutta; Wetzel, Marie-Cécile; Bartle, Laura M.; Skaletskaya, Anna; Goldmacher, Victor S.; Vallée, François et al. (2014): SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. In Clinical cancer research : an official journal of the American Association for Cancer Research 20 (17), pp. 4574–4583. DOI: 10.1158/1078-0432.CCR-14-0695.

Deguchi, S.; Katsushima, K.; Hatanaka, A.; Shinjo, K.; Ohka, F.; Wakabayashi, T. et al. (2017): Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. In Oncogene 36 (32), pp. 4629–4640. DOI: 10.1038/onc.2017.88.

Doi, Kenichiro; Li, Rongshi; Sung, Shen-Shu; Wu, Hongwei; Liu, Yan; Manieri, Wanda et al. (2012): Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. In The Journal of biological chemistry 287 (13), pp. 10224–10235. DOI: 10.1074/jbc.M111.334532.

Dominguez, Eduardo; Galmozzi, Andrea; Chang, Jae Won; Hsu, Ku-Lung; Pawlak, Joanna; Li, Weiwei et al. (2014): Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. In Nature chemical biology 10 (2), pp. 113–121. DOI: 10.1038/nchembio.1429.

Dorrance, A. M.; Neviani, P.; Ferrenchak, G. J.; Huang, X.; Nicolet, D.; Maharry, K. S. et al. (2015): Targeting leukemia stem cells in vivo with antagoniR-126 nanoparticles in acute myeloid leukemia. In Leukemia 29 (11), pp. 2143–2153. DOI: 10.1038/leu.2015.139.

Duan, Xiaoqiong; Li, Shilin; Holmes, Jacinta A.; Tu, Zeng; Li, Yujia; Cai, Dachuan et al. (2018): MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. In Journal of virology 92 (7). DOI: 10.1128/JVI.02009-17.

Dubey, Sunil Kumar; Shrinet, Jatin; Jain, Jaspreet; Ali, Shakir; Sunil, Sujatha (2017): Aedes aegypti microRNA miR-2b regulates ubiquitin-related modifier to control chikungunya virus replication. In Scientific reports 7 (1), p. 17666. DOI: 10.1038/s41598-017-18043-0.

El Hokayem, Jimmy; Weeber, Edwin; Nawaz, Zafar (2018): Loss of Angelman Syndrome Protein E6AP Disrupts a Novel Antagonistic Estrogen-Retinoic Acid Transcriptional Crosstalk in Neurons. In Molecular neurobiology 55 (9), pp. 7187–7200. DOI: 10.1007/s12035-018-0871-9.

Erkan, E. P.; Ströbel, T.; Lewandrowski, G.; Tannous, B.; Madlener, S.; Czech, T. et al. (2014): Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo. In Oncogene 33 (39), pp. 4778–4785. DOI: 10.1038/onc.2013.423.

Escobar, D.; Hepp, M. I.; Farkas, C.; Campos, T.; Sodir, N. M.; Morales, M. et al. (2015): Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicin. In Cell death & disease 6, e1816. DOI: 10.1038/cddis.2015.165.

Etemadmoghadam, Dariush; Au-Yeung, George; Wall, Meaghan; Mitchell, Chris; Kansara, Maya; Loehr, Elizabeth et al. (2013): Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. In Clinical cancer research : an official journal of the American Association for Cancer Research 19 (21), pp. 5960–5971. DOI: 10.1158/1078-0432.CCR-13-1337.

Fadini, Gian Paolo; Albiero, Mattia; Millioni, Renato; Poncina, Nicol; Rigato, Mauro; Scotton, Rachele et al. (2014): The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. In Diabetologia 57 (9), pp. 1947–1956. DOI: 10.1007/s00125-014-3300-2.

Falcão, V. C. A.; Villela, A. D.; Rodrigues-Junior, V. S.; Pissinate, K.; Eichler, P.; Pinto, A. F. M. et al. (2017): Validation of Mycobacterium tuberculosis dihydroneopterin aldolase as a molecular target
for anti-tuberculosis drug development. In Biochemical and biophysical research communications 485 (4), pp. 814–819. DOI: 10.1016/j.bbrc.2017.02.137.

Fan, Cun-Dong; Sun, Jing-Yi; Fu, Xiao-Ting; Hou, Ya-Jun; Li, Yuan; Yang, Ming-Feng et al. (2017): Astaxanthin Attenuates Homocysteine-Induced Cardiotoxicity in Vitro and in Vivo by Inhibiting Mitochondrial Dysfunction and Oxidative Damage. In Frontiers in physiology 8, p. 1041. DOI: 10.3389/fphys.2017.01041.

Fan, Cun-Dong; Sun, Jing-Yi; Fu, Xiao-Ting; Hou, Ya-Jun; Li, Yuan; Yang, Ming-Feng et al. (2017): Astaxanthin Attenuates Homocysteine-Induced Cardiotoxicity in Vitro and in Vivo by Inhibiting Mitochondrial Dysfunction and Oxidative Damage. In Frontiers in physiology 8, p. 1041. DOI: 10.3389/fphys.2017.01041.

Fang, Xia; Chen, Chiqi; Xia, Fangzhen; Yu, Zhuo; Zhang, Yaping; Zhang, Feifei et al. (2016): CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. In Journal of hematology & oncology 9 (1), p. 124. DOI: 10.1186/s13045-016-0350-6.

Feng, Biao; Cao, Yanan; Chen, Shali; Ruiz, Michael; Chakrabarti, Subrata (2014): miRNA-1 regulates endothelin-1 in diabetes. In Life sciences 98 (1), pp. 18–23. DOI: 10.1016/j.lfs.2013.12.199.

Feng, Biao; Cao, Yanan; Chen, Shali; Ruiz, Michael; Chakrabarti, Subrata (2014): Reprint of: miRNA-1 regulates endothelin-1 in diabetes. In Life sciences 118 (2), pp. 275–280. DOI: 10.1016/j.lfs.2014.10.001.

Feng, Lili; Ju, Meihua; Lee, Kei Ying V.; Mackey, Ashley; Evangelista, Mariasilvia; Iwata, Daiju et al. (2017): A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. In The American journal of pathology 187 (10), pp. 2208–2221. DOI: 10.1016/j.ajpath.2017.06.015.

Filippova, Natalia; Yang, Xiuhua; Wang, Yimin; Gillespie, G. Yancey; Langford, Cathy; King, Peter H. et al. (2011): The RNA-binding protein HuR promotes glioma growth and treatment resistance. In Molecular cancer research : MCR 9 (5), pp. 648–659. DOI: 10.1158/1541-7786.MCR-10-0325.

Finkel, Terri H.; Li, Jin; Wei, Zhi; Wang, Wei; Zhang, Haitao; Behrens, Edward M. et al. (2016): Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility. In BMC medical genetics 17, p. 24. DOI: 10.1186/s12881-016-0285-3.

Fleischmann, Katrin K.; Pagel, Philipp; Schmid, Irene; Roscher, Adelbert A. (2014): RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. In Molecular cancer 13, p. 27. DOI: 10.1186/1476-4598-13-27.

Florean, Cristina; Schnakenburger, Michael; Lee, Jin-Young; Kim, Kyung Rok; Mazumder, Aloran; Song, Sungmi et al. (2016): Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. In Oncotarget 7 (17), pp. 24027–24049. DOI: 10.18632/oncotarget.8210.

Fontanilla, C. V.; Wei, X.; Zhao, L.; Johnstone, B.; Pascuzzi, R. M.; Farlow, M. R.; Du, Y. (2012): Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis. In Neuroscience 205, pp. 185–193. DOI: 10.1016/j.neuroscience.2011.12.025.

Foster, Toshana L.; Thompson, Gary S.; Kalverda, Arnout P.; Kankanala, Jayakanth; Bentham, Matthew; Wetherill, Laura F. et al. (2014): Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. In Hepatology (Baltimore, Md.) 59 (2), pp. 408–422. DOI: 10.1002/hep.26685.

Foy, Kevin C.; Miller, Megan J.; Moldovan, Nicanor; Bozanovic, Tatjana; Carson, William E.; Kaumaya, Pravin T. P. (2012): Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel...
causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. In Oncoimmunology 1 (7), pp. 1004–1016. DOI: 10.4161/onci.21057.

Foy, Kevin Chu; Wygle, Ruthie M.; Miller, Megan J.; Overholser, Jay P.; Bekaii-Saab, Tanios; Kaumaya, Pravin T. P. (2013): Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. In Journal of immunology (Baltimore, Md. : 1950) 191 (1), pp. 217–227. DOI: 10.4049/jimmunol.1300231.

Freire, João Miguel; Rego de Figueiredo, Inês; Valle, Javier; Veiga, Ana Salomé; Andreu, David; Enguita, Francisco J.; Castanho, Miguel A. R. B. (2017): siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model. In Journal of controlled release : official journal of the Controlled Release Society 245, pp. 127–136. DOI: 10.1016/j.jconrel.2016.11.027.

Gabriely, Galina; Yi, Ming; Narayan, Ravi S.; Niers, Johanna M.; Wurdinger, Thomas; Imitola, Jaime et al. (2011): Human glioma growth is controlled by microRNA-10b. In Cancer research 71 (10), pp. 3563–3572. DOI: 10.1158/0008-5472.CAN-10-3568.

Gao, Linlin; Harhaj, Edward William (2013): HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-κB activation and HTLV-1 replication. In Journal of virology 87 (24), pp. 13640–13654. DOI: 10.1128/JVI.02006-13.

Garbuz, Tamila; Arrizabalaga, Gustavo (2017): Lack of mitochondrial MutS homolog 1 in Toxoplasma gondii disrupts maintenance and fidelity of mitochondrial DNA and reveals metabolic plasticity. In PloS one 12 (11), e0188040. DOI: 10.1371/journal.pone.0188040.
Giuriato, Sylvie; Foisseau, Marianne; Dejean, Emilie; Felsher, Dean W.; Al Saati, Talal; Demur, Cécile et al. (2010): Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. In Blood 115 (20), pp. 4061–4070. DOI: 10.1182/blood-2008-06-163386.

Gogoi, Dhrubajyoti; Baruah, Vishwa Jyoti; Chaliha, Amrita Kashyap; Kakoti, Bibhuti Bhushan; Sarma, Diganta; Buragohain, Alak Kumar (2017): Identification of novel human renin inhibitors through a combined approach of pharmacophore modelling, molecular DFT analysis and in silico screening. In Computational biology and chemistry 69, pp. 28–40. DOI: 10.1016/j.compbiolchem.2017.04.005.

Goldberg, Liat; Tijssen, Marloes R.; Birger, Yehudit; Hannah, Rebecca L.; Kinston, Sarah J.; Schütte, Judith et al. (2013): Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. In Blood 122 (15), pp. 2694–2703. DOI: 10.1182/blood-2013-01-477133.

Gombash, S. E.; Manfredsson, F. P.; Mandel, R. J.; Collier, T. J.; Fischer, D. L.; Kemp, C. J. et al. (2014): Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. In Gene therapy 21 (7), pp. 682–693. DOI: 10.1038/gt.2014.42.

Gong, Jia-Nan; Khong, Tiffany; Segal, David; Yao, Yuan; Riffkin, Chris D.; Garnier, Jean-Marc et al. (2016): Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. In Blood 128 (14), pp. 1834–1844. DOI: 10.1182/blood-2016-03-704908.

Goonawardane, Niluka; Gebhardt, Anna; Bartlett, Christopher; Pichlmair, Andreas; Harris, Mark (2017): Phosphorylation of Serine 225 in Hepatitis C Virus NS5A Regulates Protein-Protein Interactions. In Journal of virology 91 (17). DOI: 10.1128/JVI.00805-17.

Gould, Harry J.; Soignier, R. Denis; Cho, Sung R.; Hernandez, Christian; Diamond, Ivan; Taylor, Bradley K.; Paul, Dennis (2014): Ranolazine attenuates mechanical allodynia associated with demyelination injury. In Pain medicine (Malden, Mass.) 15 (10), pp. 1771–1780. DOI: 10.1111/pme.12516.

Grant, Nicola J.; Coates, Philip J.; Woods, Yvonne L.; Bray, Susan E.; Morrice, Nicholas A.; Hastie, C. James et al. (2015): Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis. In BMC cancer 15, p. 885. DOI: 10.1186/s12885-015-1691-1.

Greco, Stephanie H.; Tomkötter, Lena; Vahele, Anne-Kristin; Rokosh, Rae; Avanzi, Antonina; Mahmood, Syed Kashif et al. (2015): TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. In PloS one 10 (7), e0132786. DOI: 10.1371/journal.pone.0132786.

Grose, Julianne H.; Langston, Kelsey; Wang, Xiaohui; Squires, Shayne; Mustafi, Soumyajit Banerjee; Hayes, Whitney et al. (2015): Characterization of the Cardiac Overexpression of HSPB2 Reveals Mitochondrial and Myogenic Roles Supported by a Cardiac HspB2 Interactome. In PloS one 10 (10), e0133994. DOI: 10.1371/journal.pone.0133994.

Grzegorzewicz, Anna E.; Pham, Ha; Gund, Vijay A. K. B.; Scherman, Michael S.; North, Elton J.; Hess, Tamara et al. (2012): Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. In Nature chemical biology 8 (4), pp. 334–341. DOI: 10.1038/nchembio.794.

Gu, C.; Yang, Y.; Sompallae, R.; Xu, H.; Tompkins, V. S.; Holman, C. et al. (2016): FOXM1 is a therapeutic target for high-risk multiple myeloma. In Leukemia 30 (4), pp. 873–882. DOI: 10.1038/leu.2015.334.
Guan, Xiaoxiang; Wang, Lu; Liu, Zhenhong; Guo, Xiaofei; Jiang, Yuan; Lu, Ying et al. (2016): miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. In Journal of molecular and cellular cardiology 99, pp. 207–217. DOI: 10.1016/j.yjmcc.2016.08.016.

Gullà, A.; Hideshima, T.; Bianchi, G.; Fulciniti, M.; Kemal Samur, M.; Qi, J. et al. (2018): Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. In Leukemia 32 (4), pp. 996–1002. DOI: 10.1038/leu.2017.334.

Guo, Jigang; Dong, Qian; Fang, Zhixiang; Chen, Xi; Lu, Hongting; Wang, Kehui et al. (2010): Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. In Cancer biology & therapy 9 (6), pp. 446–452. DOI: 10.4161/cbt.9.6.10894.

Guo, Jun; Li, Cai; Yang, Chunxiao; Li, Bing; Wei, Jie; Lin, Yajun et al. (2018): Liraglutide reduces hepatic glucolipotoxicity-induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats. In Molecular medicine reports 17 (6), pp. 8316–8324. DOI: 10.3892/mmr.2018.8919.

Guo, Wei; Zhu, Chaoqun; Yin, Zhiyong; Wang, Qiu-rong; Sun, Mingming; Cao, Huojun; Greaser, Marion L. (2018): Splicing Factor RBM20 Regulates Transcriptional Network of Titin Associated and Calcium Handling Genes in The Heart. In International journal of biological sciences 14 (4), pp. 369–380. DOI: 10.7150/ijbs.24117.

Guo, Wenchang; Liu, Ruiwu; Ono, Yoko; Ma, Ai-Hong; Martinez, Anthony; Sanchez, Eduardo et al. (2012): Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. In Molecular pharmacology 82 (5), pp. 938–947. DOI: 10.1124/mol.112.079889.

Guo, Xiaoyun; Yin, Hai-feng; Li, Lei; Chen, Yi; Li, Jing; Doan, Jessica et al. (2017): Cardioprotective Role of Tumor Necrosis Factor Receptor-Associated Factor 2 by Suppressing Apoptosis and Necroptosis. In Circulation 136 (8), pp. 729–742. DOI: 10.1161/CIRCULATIONAHA.116.026240.

Gupta, Rashmi; Rodrigues Felix, Carolina; Akerman, Matthew P.; Akerman, Kate J.; Slabber, Cathryn A.; Wang, Wenjie et al. (2018): Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus. In Antimicrobial agents and chemotherapy 62 (5). DOI: 10.1128/AAC.01696-17.

Gurda, Grzegorz T.; Crozier, Stephen J.; Ji, Baoan; Ernst, Stephen A.; Logsdon, Craig D.; Rothermel, Beverly A.; Williams, John A. (2010): Regulator of calcineurin 1 controls growth plasticity of adult pancreas. In Gastroenterology 139 (2), 609-19, 619.e1-6. DOI: 10.1053/j.gastro.2010.04.050.

Habib, Abdella M.; Matsuyama, Ayako; Okorokov, Andrei L.; Santana-Varela, Sonia; Bras, Jose T.; Aloisi, Anna Maria et al. (2018): A novel human pain insensitivity disorder caused by a point mutation in ZFHX2. In Brain : a journal of neurology 141 (2), pp. 365–376. DOI: 10.1093/brain/awx326.

Halle, Bo; Thomassen, Mads; Venkatesan, Ranga; Kaimal, Vivek; Marcussen, Eric G.; Munthe, Sune et al. (2016): Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. In Journal of neuro-oncology 128 (3), pp. 395–404. DOI: 10.1007/s11060-016-2125-x.

Han, Bo-Wei; Feng, Dan-Dan; Li, Zhi-Gang; Luo, Xue-Qun; Zhang, Hua; Li, Xiao-Juan et al. (2011): A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. In Human molecular genetics 20 (24), pp. 4903–4915. DOI: 10.1093/hmg/ddr428.

Hanaford, Allison R.; Archer, Tenley C.; Price, Antoinette; Kahlert, Ulf D.; Maciaczyk, Jarek; Nikkhah, Guido et al. (2016): DiSCOVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. In Clinical
cancer research : an official journal of the American Association for Cancer Research 22 (15), pp. 3903–3914. DOI: 10.1158/1078-0432.CCR-15-3011.

Hang, Pengzhou; Zhao, Jing; Cai, Benzhi; Tian, Shanshan; Huang, Wei; Guo, Jing et al. (2015): Brain-derived neurotrophic factor regulates TRPC3/6 channels and protects against myocardial infarction in rodents. In International journal of biological sciences 11 (5), pp. 536–545. DOI: 10.7150/ijbs.10754.

Hao, Hong; Kim, Douglas S.; Klocke, Bernward; Johnson, Kory R.; Cui, Kairong; Gotoh, Norimoto et al. (2012): Transcriptional regulation of rod photoreceptor homeostasis revealed by in vivo NRL targetome analysis. In PLoS genetics 8 (4), e1002649. DOI: 10.1371/journal.pgen.1002649.

Hasan, Md Anayet; Khan, Md Arif; Datta, Amit; Mazumder, Md Habibul Hasan; Hossain, Mohammad Uzzal (2015): A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment. In Molecular immunology 65 (1), pp. 189–204. DOI: 10.1016/j.molimm.2014.12.013.

He, Ping; Staufenbiel, Matthias; Li, Rena; Shen, Yong (2014): Deficiency of patched 1-induced Gli1 signal transduction results in astrogensis in Swedish mutated APP transgenic mice. In Human molecular genetics 23 (24), pp. 6512–6527. DOI: 10.1093/hmg/ddu370.

Hennen, Eva; Safina, Dina; Haussmann, Ute; Wörsdörfer, Philipp; Edelhofer, Frank; Poetsch, Ansgar; Faissner, Andreas (2013): A LewisX glycoprotein screen identifies the low density lipoprotein receptor-related protein 1 (LRP1) as a modulator of oligodendrogenesis in mice. In The Journal of biological chemistry 288 (23), pp. 16538–16545. DOI: 10.1074/jbc.M112.419812.

Hernandez, Michael X.; Jiang, Shan; Cole, Tracy A.; Chu, Shu-Hui; Fonseca, Maria I.; Fang, Melody J. et al. (2017): Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. In Molecular neurodegeneration 12 (1), p. 66. DOI: 10.1186/s13024-017-0210-z.

Holand, T.; Riffo-Vasquez, Y.; Spina, D.; O’Connor, B.; Woisín, F.; Sand, C. et al. (2014): A role for mitogen kinase kinase 3 in pulmonary inflammation validated from a proteomic approach. In Pulmonary pharmacology & therapeutics 27 (2), pp. 156–163. DOI: 10.1016/j.pupt.2014.01.006.

Hori, Daijiro; Dunkerly-Eyring, Brittany; Nomura, Yohei; Biswas, Debjit; Steppan, Jochen; Henao-Mejia, Jorge et al. (2017): miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. In PloS one 12 (3), e0174108. DOI: 10.1371/journal.pone.0174108.

Hossain, Dewan M. S.; Panda, Abir K.; Chakrabarty, Sreeparna; Bhattacharjee, Pushpak; Kajal, Kirti; Mohanty, Suchismita et al. (2015): MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu. In Immunology 144 (4), pp. 561–573. DOI: 10.1111/imm.12397.

Hu, Tingting; Chen, Ye; Jiang, Qian; Lin, Jun; Li, Hewei; Wang, Pinda; Feng, Leping (2017): Overexpressed eNOS upregulates SIRT1 expression and protects mouse pancreatic β cells from apoptosis. In Experimental and therapeutic medicine 14 (2), pp. 1727–1731. DOI: 10.3892/etm.2017.4669.

Hu, Wei; Wang, Mian; Yin, Henghui; Yao, Chen; He, Qiong; Yin, Leping et al. (2015): MicroRNA-1298 is regulated by DNA methylation and affects vascular smooth muscle cell function by targeting connexin 43. In Cardiovascular research 107 (4), pp. 534–545. DOI: 10.1093/cvr/cvv160.

Huan, Tianxiao; Meng, Qingying; Saleh, Mohamed A.; Norlander, Allison E.; Joehanes, Roby; Zhu, Jun et al. (2015): Integrative network analysis reveals molecular mechanisms of blood pressure regulation. In Molecular systems biology 11 (1), p. 799. DOI: 10.15252/msb.20145399.
Huang, Ling; Zhang, Shu-Min; Zhang, Peng; Zhang, Xiao-Jing; Zhu, Li-Hua; Chen, Ke et al. (2014): Interferon regulatory factor 7 protects against vascular smooth muscle cell proliferation and neointima formation. In Journal of the American Heart Association 3 (5), e001309. DOI: 10.1161/JAHA.114.001309.

Huang, Qian; Zhang, Xin-Wen; Ma, Yu-Shui; Lu, Gai-Xia; Xie, Ru-Ting; Yang, Hui-Qiong et al. (2017): Up-regulated microRNA-299 corrected with poor prognosis of glioblastoma multiforme patients by targeting ELL2. In Japanese journal of clinical oncology 47 (7), pp. 590–596. DOI: 10.1093/jjco/hyw188.

Huang, Tao; Ji, Yan; Hu, Dan; Chen, Baozheng; Zhang, Hejun; Li, Chao et al. (2016): SNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression. In Oncotarget 7 (49), pp. 80990–81002. DOI: 10.18632/oncotarget.13167.

Iaconetti, Claudio; Rosa, Salvatore de; Polimeni, Alberto; Sorrentino, Sabato; Gareri, Clarice; Carino, Annarita et al. (2015): Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. In Cardiovascular research 107 (4), pp. 522–533. DOI: 10.1093/cvr/cvv141.
Jeruschke, Stefanie; Jeruschke, Kay; DiStasio, Andrew; Karaterzi, Sinem; Büscher, Anja K.; Nalbant, Perihan et al. (2015): Everolimus Stabilizes Podocyte Microtubules via Enhancing TUBB2B and DCDC2 Expression. In PloS one 10 (9), e0137043. DOI: 10.1371/journal.pone.0137043.

Jeyabal, Prince; Thandavarayan, Rajarajan A.; Joladarashi, Darukeshwara; Suresh Babu, Sahana; Krishnamurthy, Shashirekha; Bhimaraj, Arvind et al. (2016): MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1. In Biochemical and biophysical research communications 471 (4), pp. 423–429. DOI: 10.1016/j.bbrc.2016.02.065.

Jin, Hong-Jian; Jung, Segun; DebRoy, Auditi R.; Davuluri, Ramana V. (2016): Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. In Oncotarget 7 (34), pp. 54616–54626. DOI: 10.18632/oncotarget.10520.

Jin, Jing; Hu, Jinping; Zhou, Wanqi; Wang, Xiaojian; Xue, Nina et al. (2014): Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. In Biochemical pharmacology 90 (1), pp. 50–61. DOI: 10.1016/j.bcp.2014.04.010.

Jing, Yuqi; Bejarano, Marcela Toro; Zaias, Julia; Merchan, Jaime R. (2015): In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer. In Breast cancer research and treatment 149 (1), pp. 99–108. DOI: 10.1007/s10549-014-3236-8.

Jing, Yuqi; Chavez, Valery; Ban, Yuguang; Acquavella, Nicolas; El-Ashry, Doraya; Pronin, Alexey et al. (2017): Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. In Molecular cancer research : MCR 15 (10), pp. 1410–1420. DOI: 10.1158/1541-7786.MCR-17-0016.

Kalani, Anuradha; Chaturvedi, Pankaj; Maldonado, Claudio; Bauer, Philip; Joshua, Irving G.; Tyagi, Suresh C.; Tyagi, Neetu (2017): Dementia-like pathology in type-2 diabetes: A novel microRNA mechanism. In Molecular and cellular neurosciences 80, pp. 58–65. DOI: 10.1016/j.mcn.2017.02.005.

Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Döhner, Hartmut; Döhner, Konstanze; Schittenhelm, Marcus Matthias (2013): Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. In Molecular cancer 12, p. 19. DOI: 10.1186/1476-4598-12-19.

Karakikes, Ioannis; Chaanine, Antoine H.; Kang, Soojeong; Mukete, Bertrand N.; Jeong, Dongtaek; Zhang, Shihong et al. (2013): Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. In Journal of the American Heart Association 2 (2), e000078. DOI: 10.1161/JAHA.113.000078.

Karbiener, Michael; Neuhold, Claudia; Opriessnig, Peter; Prokesch, Andreas; Bogner-Strauss, Juliane G.; Scheideler, Marcel (2011): MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2. In RNA biology 8 (5), pp. 850–860. DOI: 10.4161/rna.8.5.16153.

Karolina, Dwi Setyowati; Armugam, Arumnozhiarasi; Tavintharan, Subramaniam; Wong, Michael T. K.; Lim, Su Chi; Sum, Chee Fang; Jeyaseelan, Kandiah (2011): MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. In PloS one 6 (8), e22839. DOI: 10.1371/journal.pone.0022839.

Katare, Rajesh; Riu, Federica; Mitchell, Kathryn; Gubernator, Miriam; Campagnolo, Paola; Cui, Yuxin et al. (2011): Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. In Circulation research 109 (8), pp. 894–906. DOI: 10.1161/CIRCRESAHA.111.251546.
Kaul, Malvika; Mark, Lilly; Zhang, Yongzheng; Parhi, Ajit K.; Lyu, Yi Lisa; Pawlak, Joan et al. (2015): TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. In Antimicrobial agents and chemotherapy 59 (8), pp. 4845–4855. DOI: 10.1128/AAC.00708-15.

Kedar, Rotem; Sabag, Ofra; Licthenstein, Michal; Lorberboum-Galski, Haya (2012): Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies. In Cancer 118 (24), pp. 6089–6104. DOI: 10.1002/cncr.27654.

Keersmaecker, Kim de; Porcu, Michaël; Cox, Luk; Girardi, Tiziana; Vandepoel, Roel; Beeck, Joyce Op de et al. (2014): NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. In Haematologica 99 (1), pp. 85–93. DOI: 10.3324/haematol.2013.088674.

Kim, Chan Woo; Kumar, Sandeep; Son, Dong Ju; Jang, In-Hwan; Griendling, Kathy K.; Jo, Hanjoong (2014): Prevention of abdominal aortic aneurysm by anti-microRNA-712 or anti-microRNA-205 in angiotensin II-infused mice. In Arteriosclerosis, thrombosis, and vascular biology 34 (7), pp. 1412–1421. DOI: 10.1161/ATVBAHA.113.303134.

Kim, Chan Woo; Pokutta-Paskaileva, Anastassia; Kumar, Sandeep; Timmins, Lucas H.; Morris, Andrew D.; Kang, Dong-Won et al. (2017): Disturbed Flow Promotes Arterial Stiffening Through Thrombospondin-1. In Circulation 136 (13), pp. 1217–1232. DOI: 10.1161/CIRCULATIONAHA.116.026361.

Kim, Kyu-Tae; Carroll, Adam P.; Mashkani, Baratali; Cairns, Murray J.; Small, Donald; Scott, Rodney J. (2012): MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. In PloS one 7 (9), e44546. DOI: 10.1371/journal.pone.0044546.

Kirby, Tyler J.; Walton, R. Grace; Finlin, Brian; Zhu, Beibei; Unal, Resat; Rasouli, Neda et al. (2016): Integrative mRNA-microRNA analyses reveal novel interactions related to insulin sensitivity in human adipose tissue. In Physiological genomics 48 (2), pp. 145–153. DOI: 10.1152/physiolgenomics.00071.2015.

Kirkby, Nicholas S.; Lundberg, Martina H.; Wright, William R.; Warner, Timothy D.; Paul-Clark, Mark J.; Mitchell, Jane A. (2014): COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. In PloS one 9 (6), e98165. DOI: 10.1371/journal.pone.0098165.

Kling, Angela; Lukat, Peer; Almeida, Deepak V.; Bauer, Armin; Fontaine, Evelyne; Sordello, Sylvie et al. (2015): Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. In Science (New York, N.Y.) 348 (6239), pp. 1106–1112. DOI: 10.1126/science.aaa4690.

Ko, Kichul; Wang, Jianing; Perper, Stuart; Jiang, Yulei; Yanez, Denisse; Kaverina, Natalya et al. (2016): Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. In Arthritis & rheumatology (Hoboken, N.J.) 68 (11), pp. 2740–2751. DOI: 10.1002/art.39744.

Koss, Brian; Ryan, Jeremy; Budhraja, Amit; Szarama, Katherine; Yang, Xue; Bathina, Madhavi et al. (2016): Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. In Oncotarget 7 (10), pp. 11500–11511. DOI: 10.18632/oncotarget.7204.

Krishnan, Navasona; Konidaris, Konstantis F.; Gasser, Gilles; Tonks, Nicholas K. (2018): A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. In The Journal of biological chemistry 293 (5), pp. 1517–1525. DOI: 10.1074/jbc.C117.819110.
Krishnan, Navasona; Koveal, Dorothy; Miller, Daniel H.; Xue, Bin; Akshinthala, Sai Dipikaa; Kragelj, Jaka et al. (2014): Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. In Nature chemical biology 10 (7), pp. 558–566. DOI: 10.1038/nchembio.1528.

Kumarswamy, Regalla; Lyon, Alexander R.; Volkmann, Ingo; Mills, Adam M.; Brethauer, Julia; Pahuja, Aanchal et al. (2012): SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. In European heart journal 33 (9), pp. 1067–1075. DOI: 10.1093/eurheartj/ehs043.

Kuner, Ruprecht; Fälth, Maria; Pressinotti, Nicole Chui; Brase, Jan C.; Puig, Sabrina Balaguer; Metzger, Jennifer et al. (2013): The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. In Journal of molecular medicine (Berlin, Germany) 91 (2), pp. 237–248. DOI: 10.1007/s00109-012-0949-1.

Kusio-Kobialka, Monika; Dudka-Ruszkowska, Wioleta; Ghizzoni, Massimo; Dekker, Frank J.; Piwocka, Katarzyna (2013): Inhibition of PCAF by anacardic acid derivative leads to apoptosis and breaks resistance to DNA damage in BCR-ABL-expressing cells. In Anti-cancer agents in medicinal chemistry 13 (5), pp. 762–767. DOI: 10.2174/1871520611313050010.

Lacraz, Grégory P. A.; Junker, Jan Philipp; Gladka, Monika M.; Molenaar, Bas; Scholman, Koen T.; Vigil-Garcia, Marta et al. (2017): Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury. In Circulation 136 (15), pp. 1396–1409. DOI: 10.1161/CIRCULATIONAHA.117.027832.

Laganà, A.; Perumal, D.; Melnekoff, D.; Readhead, B.; Kidd, B. A.; Leshchenko, V. et al. (2018): Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. In Leukemia 32 (1), pp. 120–130. DOI: 10.1038/leu.2017.197.

Lagautriere, Thomas; Bashiri, Ghader; Paterson, Neil G.; Berny, Michael; Cook, Gregory M.; Baker, Edward N. (2014): Characterization of the proline-utilization pathway in Mycobacterium tuberculosis through structural and functional studies. In Acta crystallographica. Section D, Biological crystallography 70 (Pt 4), pp. 968–980. DOI: 10.1107/S1399004713034391.

Laher, Ismail; Beam, Julianne; Botta, Amy; Barendregt, Rebekah; Sulistyoningrum, Dian; Devlin, Angela et al. (2013): Short-term exercise worsens cardiac oxidative stress and fibrosis in 8-month-old db/db mice by depleting cardiac glutathione. In Free radical research 47 (1), pp. 44–54. DOI: 10.3109/10715762.2012.737463.

Lai, Yen-Chun; Tabima, Diana M.; Dube, John J.; Hughan, Kara S.; Vanderpool, Rebecca R.; Goncharov, Dmitry A. et al. (2016): SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. In Circulation 133 (8), pp. 717–731. DOI: 10.1161/CIRCULATIONAHA.115.018935.

Lakhter, Alexander J.; Pratt, Rachel E.; Moore, Rachel E.; Doucette, Kaitlin K.; Maier, Bernhard F.; DiMeglio, Linda A.; Sims, Emily K. (2018): Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. In Diabetologia 61 (5), pp. 1124–1134. DOI: 10.1007/s00125-018-4559-5.

Lalli, M. A.; Bettcher, B. M.; Arcila, M. L.; Garcia, G.; Guzman, C.; Madrigal, L. et al. (2015): Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer’s disease. In Molecular psychiatry 20 (11), pp. 1294–1300. DOI: 10.1038/mp.2015.131.

Lavoie, Jessie R.; Creskey, Marybeth M.; Muradia, Gauri; Bell, Gillian I.; Sherman, Stephen E.; Gao, Jun et al. (2016): Brief Report: Elastin Microfibril Interface 1 and Integrin-Linked Protein Kinase Are
Novel Markers of Islet Regenerative Function in Human Multipotent Mesenchymal Stromal Cells. In Stem cells (Dayton, Ohio) 34 (8), pp. 2249–2255. DOI: 10.1002/stem.2385.

Leber, Andrew; Bassaganya-Riera, Josep; Tubau-Juni, Nuria; Zoccoli-Rodriguez, Victoria; Lu, Pinyi; Godfrey, Victoria et al. (2017): Lanthionine Synthetase C-Like 2 Modulates Immune Responses to Influenza Virus Infection. In Frontiers in immunology 8, p. 178. DOI: 10.3389/fimmu.2017.00178.

Lechman, Eric R.; Gentner, Bernhard; Ng, Stanley W. K.; Schoof, Erwin M.; van Galen, Peter; Kennedy, James A. et al. (2016): miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. In Cancer cell 29 (2), pp. 214–228. DOI: 10.1016/j.ccell.2015.12.011.

Ledri, Marco; Sørensen, Andreas T.; Madsen, Marita G.; Christiansen, Søren H.; Ledri, Litsa Nikitidou; Cifra, Alessandra et al. (2015): Differential Effect of Neuropeptides on Excitatory Synaptic Transmission in Human Epileptic Hippocampus. In The Journal of neuroscience : the official journal of the Society for Neuroscience 35 (26), pp. 9622–9631. DOI: 10.1523/JNEUROSCI.3973-14.2015.

Lee, B. J.; Shah, N. P. (2017): Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. In Leukemia 31 (5), pp. 1096–1107. DOI: 10.1038/leu.2016.353.

Lee, John K.; Bangayan, Nathanael J.; Chai, Timothy; Smith, Bryan A.; Pariva, Tiffany E.; Yun, Sangwon et al. (2018): Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. In Proceedings of the National Academy of Sciences of the United States of America 115 (19), E4473-E4482. DOI: 10.1073/pnas.1802354115.

Lee, Jun-Han; Lee, Joo-Hyung; Lee, Sang Hyuk; Do, Sung-Im; Cho, Sung-Dae; Forslund, Ola et al. (2016): TPL2 Is an Oncogenic Driver in Keratocanthoma and Squamous Cell Carcinoma. In Cancer research 76 (22), pp. 6712–6722. DOI: 10.1158/0008-5472.CAN-15-3274.

Leffort, Sylvain; Joffre, Carine; Kieffer, Yann; Givel, Anne-Marie; Bourachot, Brigitte; Zago, Giulia et al. (2014): Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. In Autophagy 10 (12), pp. 2122–2142. DOI: 10.4161/15548627.2014.981788.

Lev, Nirit; Barhum, Yael; Ben-Zur, Tali; Aharony, Israel; Trifonov, Lena; Regev, Noa et al. (2015): A DJ-1 Based Peptide Attenuates Dopaminergic Degeneration in Mice Models of Parkinson's Disease via Enhancing Nrf2. In PloS one 10 (5), e0127549. DOI: 10.1371/journal.pone.0127549.

Li, Guanzhang; Wang, Zheng; Zhang, Chuanbao; Liu, Xing; Cai, Jinquan; Wang, Zhiliang et al. (2017): Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. In Oncoimmunology 6 (8), e1328339. DOI: 10.1080/2162402X.2017.1328339.

Li, Huaping; Zhang, Xiaorong; Wang, Feng; Zhou, Ling; Yin, Zhongwei; Fan, Jiahui et al. (2016): MicroRNA-21 Lowers Blood Pressure in Spontaneous Hypertensive Rats by Upregulating Mitochondrial Translation. In Circulation 134 (10), pp. 734–751. DOI: 10.1161/CIRCULATIONAHA.116.023926.

Li, Mei; Yasumura, Douglas; Ma, Aye Aye K.; Matthes, Michael T.; Yang, Haidong; Nielson, Gregory et al. (2013): Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. In PloS one 8 (2), e56026. DOI: 10.1371/journal.pone.0056026.

Li, Qi; Lee, Cheng Hian; Peters, Lauren A.; Mastropaolo, Lucas A.; Thoeni, Cornelio; Elkadri, Abdul et al. (2016): Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. In Gastroenterology 150 (5), pp. 1196–1207. DOI: 10.1053/j.gastro.2016.01.031.
Li, Shu-Hong; Guo, Jian; Wu, Jun; Sun, Zhuo; Han, Mihan; Shan, Sze Wan et al. (2013): miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodeling. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27 (10), pp. 4254–4265. DOI: 10.1096/fj.13-231688.

Li, Sichen; Chowdhury, Reshmi; Liu, Fei; Chou, Arthur P.; Li, Tie; Mody, Reema R. et al. (2014): Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. In Clinical cancer research : an official journal of the American Association for Cancer Research 20 (22), pp. 5808–5822. DOI: 10.1158/1078-0432.CCR-14-0234.

Li, Xiang; Jiang, Xiao-Yan; Ge, Jin; Wang, Jing; Chen, Guo-Jun; Xu, Liang et al. (2014): Aberrantly expressed IncRNAs in primary varicose great saphenous veins. In PloS one 9 (1), e86156. DOI: 10.1371/journal.pone.0086156.

Li, Yang; Tao, Jie; Zhang, Jian; Tian, Xiaoxiang; Liu, Shaowei; Sun, Mingyu et al. (2012): Cellular repressor E1A-stimulated genes controls phenotypic switching of adventitial fibroblasts by blocking p38MAPK activation. In Atherosclerosis 225 (2), pp. 304–314. DOI: 10.1016/j.atherosclerosis.2012.08.015.

Li, Yaohua; Huang, Cheng; Feng, Peimin; Jiang, Yanping; Wang, Wei; Zhou, Dong; Chen, Lei (2016): Aberrant expression of miR-153 is associated with overexpression of hypoxia-inducible factor-1α in refractory epilepsy. In Scientific reports 6, p. 32091. DOI: 10.1038/srep32091.

Li, Yikun; Yue, Ping; Deng, Xingming; Ueda, Takeshi; Fukunaga, Rikiro; Khuri, Fadlo R.; Sun, Shi-Yong (2010): Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and elf4E assembly through direct dephosphorylation of Mnk and elf4E. In Neoplasia (New York, N.Y.) 12 (10), pp. 848–855. DOI: 10.1593/neo.10704.

Li, Yonggang; Lein, Pamela J.; Ford, Gregory D.; Liu, Cuimei; Stovall, Kyndra C.; White, Todd E. et al. (2015): Neuregulin-1 inhibits neuroinflammatory responses in a rat model of organophosphate-nerve agent-induced delayed neuronal injury. In Journal of neuroinflammation 12, p. 64. DOI: 10.1186/s12974-015-0283-y.

Liang, Yongjun; Yu, Bo; Wang, Yueqian; Qiao, Zhengdong; Cao, Ting; Zhang, Peng (2017): Duodenal long noncoding RNAs are associated with glycemic control after bariatric surgery in high-fat diet-induced diabetic mice. In Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 13 (7), pp. 1212–1226. DOI: 10.1016/j.soard.2017.02.010.

Liao, Zhicong; Wang, Xiaojun; Liang, Hongwei; Yu, Ao; Ur Rehman, Uzair; Fan, Qian et al. (2017): miR-1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src. In Cancer medicine 6 (12), pp. 2957–2965. DOI: 10.1002/cam4.1214.

Litvak, Vladimir; Ratushny, Alexander V.; Lampano, Aaron E.; Schmitz, Frank; Huang, Albert C.; Raman, Ayush et al. (2012): A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. In Nature 490 (7420), pp. 421–425. DOI: 10.1038/nature11428.

Liu, Hsiu-Yu; Tuckett, Andrea Z.; Fennell, Myles; Garippa, Ralph; Zakrzewski, Johannes L. (2018): Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation. In Investigational new drugs 36 (4), pp. 590–600. DOI: 10.1007/s10637-017-0557-6.

Liu, Tong Ming; Guo, Xi Min; Tan, Hwee San; Hui, James H.; Lim, Bing; Lee, Eng Hin (2011): Zinc-finger protein 145, acting as an upstream regulator of SOX9, improves the differentiation potential of human mesenchymal stem cells for cartilage regeneration and repair. In Arthritis and rheumatism 63 (9), pp. 2711–2720. DOI: 10.1002/art.30430.
Liu, Wenzhi; Li, Mengkao; Chen, Xiangming; Zhu, Shan; Shi, Hailong; Zhang, Dawei et al. (2018): MicroRNA-1 suppresses proliferation, migration and invasion by targeting Notch2 in esophageal squamous cell carcinoma. In Scientific reports 8 (1), p. 5183. DOI: 10.1038/s41598-018-23421-3.

Liu, Xiujie; Huang, Xiaoli; Lin, Wanhua; Wang, Dongye; Diao, Yanyan; Li, Honglin et al. (2011): New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein. In Bioorganic & medicinal chemistry letters 21 (10), pp. 2949–2952. DOI: 10.1016/j.bmcl.2011.03.063.

Liu, Yanping; Lu, Zhengyu; Cui, Mei; Yang, Qi; Tang, Yuping; Dong, Qiang (2016): Tissue kallikrein protects SH-SY5Y neuronal cells against oxygen and glucose deprivation-induced injury through bradykinin B2 receptor-dependent regulation of autophagy induction. In Journal of neurochemistry 139 (2), pp. 208–220. DOI: 10.1111/jnc.13690.

Lobo, D. S.; Aleksandrova, L.; Knight, J.; Casey, D. M.; el-Guebaly, N.; Nobrega, J. N.; Kennedy, J. L. (2015): Addiction-related genes in gambling disorders: new insights from parallel human and preclinical models. In Molecular psychiatry 20 (8), pp. 1002–1010. DOI: 10.1038/mp.2014.113.

Long, Jianyin; Wang, Yin; Wang, Wenjian; Chang, Benny H. J.; Danesh, Farhad R. (2011): MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. In The Journal of biological chemistry 286 (13), pp. 11837–11848. DOI: 10.1074/jbc.M110.194969.

Losiewicz, Mandy K.; Fort, Patrice E. (2011): Diabetes impairs the neuroprotective properties of retinal alpha-crystallins. In Investigative ophthalmology & visual science 52 (9), pp. 5034–5042. DOI: 10.1167/iovs.10-6931.

Lu, L.; Chen, X. M.; Tao, H. M.; Xiong, W.; Jie, S. H.; Li, H. Y. (2015): Regulation of the expression of zinc finger protein genes by microRNAs enriched within acute lymphoblastic leukemia-derived microvesicles. In Genetics and molecular research : GMR 14 (4), pp. 11884–11895. DOI: 10.4238/2015.October.5.2.

Luo, Jiaoyang; Kong, Weijun; Yang, Meihsua (2014): HJC, a new arylnaphthalene lignan isolated from Justicia procumbens, causes apoptosis and caspase activation in K562 leukemia cells. In Journal of pharmacological sciences 125 (4), pp. 355–363. DOI: 10.1254/jphs.13211fp.

Ma, Hayley; Nguyen, Bao; Li, Li; Greenblatt, Sarah; Williams, Allen; Zhao, Ming et al. (2014): TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. In Blood 123 (10), pp. 1525–1534. DOI: 10.1182/blood-2013-08-523035.

Macioca, Paul M.; Wawrzyniecka, Patrycja A.; Philip, Brian; Ricciardelli, Ida; Akarca, Ayse U.; Onuoha, Shimobi C. et al. (2017): Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. In Nature medicine 23 (12), pp. 1416–1423. DOI: 10.1038/nm.4444.

Mack, Stephen C.; Agnihotri, Sameer; Bertrand, Kelsey C.; Wang, Xin; Shih, David J.; Witt, Hendrik et al. (2015): Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. In Clinical cancer research : an official journal of the American Association for Cancer Research 21 (16), pp. 3750–3758. DOI: 10.1158/1078-0432.CCR-14-2650.

Mahendiran, Dharmasivam; Kumar, Raju Senthil; Viswanathan, Vijayan; Velmurugan, Devadasan; Rahiman, Azil Kalilur (2017): In vitro and in vivo anti-proliferative evaluation of bis(4′-(4-tolyl)-2,2′:6′,2″-terpyridine)copper(II) complex against Ehrlich ascites carcinoma tumors. In Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 22 (7), pp. 1109–1122. DOI: 10.1007/s00775-017-1488-6.
Mallipattu, Sandeep K.; Liu, Ruijie; Zhong, Yifei; Chen, Ed Y.; D'Agati, Vivette; Kaufman, Lewis et al. (2013): Expression of HIV transgene aggravates kidney injury in diabetic mice. In Kidney international 83 (4), pp. 626–634. DOI: 10.1038/ki.2012.445.

Mandolini, C.; Santovito, D.; Marcantonio, P.; Buttitta, F.; Bucci, M.; Ucchino, S. et al. (2015): Identification of microRNAs 758 and 33b as potential modulators of ABCA1 expression in human atherosclerotic plaques. In Nutrition, metabolism, and cardiovascular diseases : NMCD 25 (2), pp. 202–209. DOI: 10.1016/j.numecd.2014.09.005.

Manikandan, A.; Moharil, Pearl; Sathishkumar, M.; Muñoz-Garay, C.; Sivakumar, A. (2017): Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential. In European journal of medicinal chemistry 141, pp. 417–426. DOI: 10.1016/j.ejmech.2017.09.076.

Manzo, Teresa; Sturmheit, Tabea; Basso, Veronica; Petrozziello, Elisabetta; Hess Michelini, Rodrigo; Riba, Michela et al. (2017): T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors. In Cancer research 77 (3), pp. 658–671. DOI: 10.11158/0008-5472.CAN-16-0725.

Mateo, Juan L.; van den Berg, Debbie L. C.; Haeussler, Maximilian; Drechsel, Daniela; Gaber, Zachary B.; Castro, Diogo S. et al. (2015): Characterization of the neural stem cell gene regulatory network identifies OLIG2 as a multifunctional regulator of self-renewal. In Genome research 25 (1), pp. 41–56. DOI: 10.1101/gr.173435.114.

Mazurek, Anthony; Park, Youngkyu; Miething, Cornelius; Wilkinson, John E.; Gillis, Jesse; Lowe, Scott W. et al. (2014): Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. In Cell reports 7 (6), pp. 1887–1899. DOI: 10.1016/j.celrep.2014.05.019.

McCarthy, Anna R.; Sachweh, Marijke C. C.; Higgins, Maureen; Campbell, Johanna; Drummond, Catherine J.; van Leeuwen, Ingeborg M. M. et al. (2013): Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. In Molecular cancer therapeutics 12 (4), pp. 352–360. DOI: 10.1158/1535-7163.MCT-12-0900.

McLendon, Patrick M.; Davis, Gregory; Gulick, James; Singh, Sonia R.; Xu, Na; Salomonis, Nathan et al. (2017): An Unbiased High-Throughput Screen to Identify Novel Effectors That Impact on Cardiomyocyte Aggregate Levels. In Circulation research 121 (6), pp. 604–616. DOI: 10.1161/CIRCRESAHA.117.310945.

Meng, Xiaoxue; Ji, Yuqiang; Wan, Zhaofei; Zhao, Bo; Feng, Chuanjie; Zhao, Jiang et al. (2017): Inhibition of miR-363 protects cardiomyocytes against hypoxia-induced apoptosis through regulation of Notch signaling. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 90, pp. 509–516. DOI: 10.1016/j.biopharm.2017.03.080.

Mérito-Zamorano, Cristina; Hernández-Guillamon, Mar; Jullienne, Amandine; Le Béhot, Audrey; Bardou, Isabelle; Parés, Mireia et al. (2015): NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke. In Stroke 46 (2), pp. 477–484. DOI: 10.1161/STROKEAHA.114.006826.
Mi, Xuhua; Tang, Wanxin; Chen, Xiaolei; Liu, Fei; Tang, Xiaohong (2016): Mitofusin 2 attenuates the histone acetylation at collagen IV promoter in diabetic nephropathy. In Journal of molecular endocrinology 57 (4), pp. 233–249. DOI: 10.1530/JME-16-0031.

Migliavacca, Jessica; Percio, Stefano; Valsecchi, Roberta; Ferrero, Elisabetta; Spinelli, Antonello; Ponzoni, Maurilio et al. (2016): Hypoxia inducible factor-1α regulates a pro-invasive phenotype in acute monocytic leukemia. In Oncotarget 7 (33), pp. 53540–53557. DOI: 10.18632/oncotarget.10660.

Minagawa, Kentaro; Jamil, Muhammad O.; Al-Obaidi, Mustafa; Pereboeva, Larisa; Salzman, Donna; Erba, Harry P. et al. (2016): In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. In PloS one 11 (12), e0166891. DOI: 10.1371/journal.pone.0166891.

Minagawa, Kentaro; Jamil, Muhammad O.; Al-Obaidi, Mustafa; Pereboeva, Larisa; Salzman, Donna; Erba, Harry P. et al. (2017): Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. In PloS one 12 (2), e0172640. DOI: 10.1371/journal.pone.0172640.

Minami, J.; Suzuki, R.; Mazitschek, R.; Gorgun, G.; Ghosh, B.; Cirstea, D. et al. (2014): Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. In Leukemia 28 (3), pp. 680–689. DOI: 10.1038/leu.2013.231.

Mocharla, Pavan; Briand, Sylvie; Giannotti, Giovanna; Dörries, Carola; Jakob, Philipp; Paneni, Francesco et al. (2013): AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. In Blood 121 (1), pp. 226–236. DOI: 10.1182/blood-2012-01-407106.

Molinolo, Alfredo A.; Marsh, Christina; El Dinali, Mohamed; Gangane, Nitin; Jennison, Kaitlin; Hewitt, Stephen et al. (2012): mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. In Clinical cancer research : an official journal of the American Association for Cancer Research 18 (9), pp. 2558–2568. DOI: 10.1158/1078-0432.CCR-11-2824.

Moradi-Kalbolandi, Shima; Davani, Dariush; Golkar, Majid; Habibi-Anbouhi, Mahdi; Abolhassani, Mohsen; Shokrgozar, Mohammad Ali (2016): Soluble Expression and Characterization of a New scFv Directed to Human CD123. In Applied biochemistry and biotechnology 178 (7), pp. 1390–1406. DOI: 10.1007/s12010-015-1954-y.

Morris, Valerie A.; Cummings, Carrie L.; Korb, Brendan; Boaglio, Sean; Oehler, Vivian G. (2016): Deregulated KLF4 Expression in Myeloid Leukemias Alters Cell Proliferation and Differentiation through MicroRNA and Gene Targets. In Molecular and cellular biology 36 (4), pp. 559–573. DOI: 10.1128/MCB.00712-15.

Mortensen, Rasmus; Nissen, Thomas Nørrelykke; Fredslund, Sine; Rosenkrands, Ida; Christensen, Jan Pravsgaard; Andersen, Peter; Dietrich, Jes (2016): Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children. In Scientific reports 6, p. 22030. DOI: 10.1038/srep22030.

Mugumbate, Grace; Abrahams, Katherine A.; Cox, Jonathan A. G.; Papadatos, George; van Westen, Gerard; Lelievre, Joël et al. (2015): Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation. In PloS one 10 (3), e0121492. DOI: 10.1371/journal.pone.0121492.

Murai, Marcelo J.; Chruszcz, Maksymilian; Reddy, Gireesh; Grembecka, Jolanta; Cierpicki, Tomasz (2011): Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. In The Journal of biological chemistry 286 (36), pp. 31742–31748. DOI: 10.1074/jbc.M111.258186.
Nadiri, Amal; Jundi, Malek; El Akoum, Souhad; Hassan, Ghada S.; Yacoub, Daniel; Mourad, Walid (2015): Involvement of the cytoplasmic cysteine-238 of CD40 in its up-regulation of CD23 expression and its enhancement of TLR4-triggered responses. In International immunology 27 (11), pp. 555–565. DOI: 10.1093/intimm/dxv030.

Nag, Jeetendra Kumar; Srivastava, Nidhi; Tiwari, Manish; Gupta, Chhedi lal; Bajpai, Preeti; Chahar, Dhanvantri; Misra-Bhattacharya, Shailja (2014): Wolbachia translation initiation factor-1 is copiously expressed by the adult, microfilariae and infective larvae of Brugia malayi and competitively inhibited by tetracycline. In Acta tropica 138, pp. 51–59. DOI: 10.1016/j.actatropica.2014.04.033.

Nam, Sangkil; Xie, Jun; Perkins, Angela; Ma, Yuelong; Yang, Fan; Wu, Jun et al. (2012): Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. In Molecular oncology 6 (5), pp. 484–493. DOI: 10.1016/j.molonc.2012.05.002.

Naqvi, Afsar R.; Seal, Alexandra; Shango, Jennifer; Brambila, Maria F.; Martinez, Gloria; Chapa, Gabriela et al. (2018): Herpesvirus-encoded microRNAs detected in human gingiva alter host cell transcriptome and regulate viral infection. In Biochimica et biophysica acta. Gene regulatory mechanisms 1861 (5), pp. 497–508. DOI: 10.1016/j.bbagrm.2018.03.001.

Naqvi, Afsar R.; Shango, Jennifer; Seal, Alexandra; Shukla, Deepak; Nares, Salvador (2018): Viral miRNAs Alter Host Cell miRNA Profiles and Modulate Innate Immune Responses. In Frontiers in immunology 9, p. 433. DOI: 10.3389/fimmu.2018.00433.

Nathwani, Seema-Maria; Greene, Lisa M.; Butini, Stefania; Campiani, Giuseppe; Williams, D. Clive; Samali, Afshin et al. (2016): The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. In International journal of oncology 49 (1), pp. 74–88. DOI: 10.3892/ijo.2016.3518.

Naz, Farha; Sami, Neha; Naqvi, Abu Turab; Islam, Asimul; Ahmad, Faizan; Imtaiyaz Hassan, Md (2017): Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays. In Journal of biomolecular structure & dynamics 35 (14), pp. 3194–3203. DOI: 10.1080/07391102.2016.1249958.

Neef, Stefan; Steffens, Alexander; Pellicena, Patricia; Mustroph, Julian; Lebek, Simon; Ort, Katharina R. et al. (2018): Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor. In Journal of molecular and cellular cardiology 115, pp. 73–81. DOI: 10.1016/j.yjmcc.2017.12.015.

Neelakantan, Harshini; Vance, Virginia; Wetzel, Michael D.; Wang, Hua-Yu Leo; McHardy, Stanton F.; Finnerty, Celeste C. et al. (2018): Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. In Biochemical pharmacology 147, pp. 141–152. DOI: 10.1016/j.bcp.2017.11.007.

Nesvick, Cody L.; Zhang, Chao; Edwards, Nancy A.; Montgomery, Blake K.; Lee, Michaela; Yang, Chunzhang et al. (2016): ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. In Journal of neuro-oncology 130 (1), pp. 111–122. DOI: 10.1007/s11060-016-2240-8.

Nguyen, Thuy-Vi V.; Shen, Lin; Vander Griend, Lilith; Quach, Lisa N.; Belichenko, Nadia P.; Saw, Nay et al. (2014): Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice. In Journal of Alzheimer's disease : JAD 42 (2), pp. 459–483. DOI: 10.3233/JAD-140036.

Nhili, Raja; Peixoto, Paul; Depauw, Sabine; Flajollet, Sébastien; Dezitter, Xavier; Munde, Manoj M. et al. (2013): Targeting the DNA-binding activity of the human ERG transcription factor using new
heterocyclic dithiophene diamidines. In Nucleic acids research 41 (1), pp. 125–138. DOI: 10.1093/nar/gks971.

Nihei, Yoshihiro; Ito, Daisuke; Okada, Yohei; Akamatsu, Wado; Yagi, Takuya; Yoshizaki, Takahito et al. (2013): Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. In The Journal of biological chemistry 288 (12), pp. 8043–8052. DOI: 10.1074/jbc.M112.408211.

Ningappa, Mylarappa; So, Juhoon; Glessner, Joseph; Ashokkumar, Chethan; Ranganathan, Sarangarajan; Min, Jun et al. (2013): The Role of ARF6 in Biliary Atresia. In PloS one 10 (9), e0138381. DOI: 10.1371/journal.pone.0138381.

Nuñez-Durán, Esther; Aghajan, Mariam; Amrutkar, Manoj; Sütt, Silva; Cansby, Emmelie; Booten, Sheri L. et al. (2018): Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. In Hepatology communications 2 (1), pp. 69–83. DOI: 10.1002/hepc.1128.

Oberbach, Andreas; Jehmlich, Nico; Schlichting, Nadine; Heinrich, Marco; Lehmann, Stefanie; Wirth, Henry et al. (2013): Molecular fingerprint of high fat diet induced urinary bladder metabolic dysfunction in a rat model. In PloS one 8 (6), e66636. DOI: 10.1371/journal.pone.0066636.

Ocloń, Ewa; Latacz, Anna; Zubel-Łojek, Joanna; Pierzchala-Koziec, Krystyna (2016): Hyperglycemia-induced changes in miRNA expression patterns in epicardial adipose tissue of piglets. In The Journal of endocrinology 229 (3), pp. 259–266. DOI: 10.1530/JOE-15-0495.

O'Hear, Carol; Heiber, Joshua F.; Schubert, Ingo; Fey, Georg; Geiger, Terrence L. (2015): Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. In Haematologica 100 (3), pp. 336–344. DOI: 10.3324/haematol.2014.112748.

Owens, A. Phillip; Edwards, Todd L.; Antoniak, Silvio; Geddings, Julia E.; Jahangir, Eiman; Wei, Wei-Qi et al. (2015): Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm. In Arteriosclerosis, thrombosis, and vascular biology 35 (9), pp. 2032–2041. DOI: 10.1161/ATVBAHA.115.305537.

Ozer, Haticce Gulcin; El-Gamal, Dalia; Powell, Ben; Hing, Zachary A.; Blachly, James S.; Harrington, Bonnie et al. (2018): BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. In Cancer discovery 8 (4), pp. 458–477. DOI: 10.1158/2158-8290.CD-17-0902.

Pan, Yinghong; Robertson, Gordon; Pedersen, Lykke; Lim, Emilia; Hernandez-Herrera, Anadulce; Rowat, Amy C. et al. (2016): miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. In Oncotarget 7 (18), pp. 25930–25948. DOI: 10.18632/oncotarget.8412.

Panguluri, Siva K.; Tur, Jared; Chapalamadugu, Kalyan C.; Katnik, Chris; Cuevas, Javier; Tipparaju, Srinivas M. (2013): MicroRNA-301a mediated regulation of Kv4.2 in diabetes: identification of key modulators. In PloS one 8 (4), e60545. DOI: 10.1371/journal.pone.0060545.

Paul, P. J.; Raghu, D.; Chan, A-L; Gulati, T.; Lambeth, L.; Takano, E. et al. (2016): Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. In Oncogene 35 (48), pp. 6235–6245. DOI: 10.1038/onc.2016.159.
Peng, Fuwang; Yao, Honghong; Akturk, Halis Kaan; Buch, Shilpa (2012): Platelet-derived growth factor CC-mediated neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta. In PloS one 7 (10), e47572. DOI: 10.1371/journal.pone.0047572.

Piccinini, Anna Maria; Knebl, Kerstin; Rek, Angelika; Wildner, Gerild; Diedrichs-Möhring, Maria; Kungl, Andreas J. (2010): Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. In The Journal of biological chemistry 285 (12), pp. 8782–8792. DOI: 10.1074/jbc.M109.043299.

Pilot-Storck, Fanny; Chopin, Emilie; Rual, Jean-François; Baudot, Anais; Dobrokhotov, Pavel; Robinson-Rechavi, Marc et al. (2010): Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. In Molecular & cellular proteomics : MCP 9 (7), pp. 1578–1593. DOI: 10.1074/mcp.M900568-MCP200.

Poli, Giada; Cantini, Giulia; Armignacco, Roberta; Fucci, Rossella; Santi, Raffaella; Canu, Letizia et al. (2016): Metformin as a new anti-cancer drug in adrenocortical carcinoma. In Oncotarget 7 (31), pp. 49636–49648. DOI: 10.18632/oncotarget.10421.

Ponath, Gerald; Ramanan, Sriram; Mubarak, Mayyan; Housley, William; Lee, Seunghoon; Sahinkaya, F. Rezan et al. (2017): Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology. In Brain : a journal of neurology 140 (2), pp. 399–413. DOI: 10.1093/brain/aww298.

Potenza, Nicoletta; Mosca, Nicola; Mondola, Paolo; Damiano, Simona; Russo, Aniello; Felice, Bruna de (2018): Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis. In Biochimica et biophysica acta. Molecular basis of disease 1864 (1), pp. 317–323. DOI: 10.1016/j.bbadis.2017.09.024.

Pryce, G.; Cabranes, A.; Fernández-Ruiz, J.; Bisogno, T.; Di Marzo, V.; Long, J. Z. et al. (2013): Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amidase hydrolase inhibitors. In Multiple sclerosis (Houndmills, Basingstoke, England) 19 (14), pp. 1896–1904. DOI: 10.1177/1352458513485982.

Rafiq, S.; Purdon, T. J.; Daniyan, A. F.; Koneru, M.; Liu, C. et al. (2017): Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. In Leukemia 31 (8), pp. 1788–1797. DOI: 10.1038/leu.2016.373.

Rak, Roni; Haklai, Roni; Elad-Tzfadia, Galit; Wolfson, Haim J.; Carmeli, Shmuel; Koo, Yoel (2014): Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. In Oncoscience 1 (1), pp. 39–48. DOI: 10.18632/oncoscience.7.

Rakhade, Sanjay N.; Fitzgerald, Erin F.; Klein, Peter M.; Zhou, Chengwen; Sun, Hongyu; Huganir, Richard L. et al. (2012): Glutamate receptor 1 phosphorylation at serine 831 and 845 modulates seizure susceptibility and hippocampal hyperexcitability after early life seizures. In The Journal of neuroscience : the official journal of the Society for Neuroscience 32 (49), pp. 17800–17812. DOI: 10.1523/JNEUROSCI.6121-11.2012.

Ramanan, Vijay K.; Risacher, Shannon L.; Nho, Kwangskik; Kim, Sungeun; Shen, Li; McDonald, Brenna C. et al. (2015): GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. In Brain : a journal of neurology 138 (Pt 10), pp. 3076–3088. DOI: 10.1093/brain/awv231.

Ran, Leili; Sirota, Inna; Cao, Zhen; Murphy, Devan; Chen, Yuedan; Shukla, Shipra et al. (2015): Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. In Cancer discovery 5 (3), pp. 304–315. DOI: 10.1158/2159-8290.CD-14-0985.
Rangrez, Ashraf Yusuf; Hoppe, Phillip; Kuhn, Christian; Zille, Elisa; Frank, Johanne; Frey, Norbert; Frank, Derk (2017): MicroRNA miR-301a is a novel cardiac regulator of Cofilin-2. In PloS one 12 (9), e0183901. DOI: 10.1371/journal.pone.0183901.

Rasanen, Kati; Sriswasdi, Sira; Valiga, Alexander; Tang, Hsin-Yao; Zhang, Gao; Perego, Michela et al. (2013): Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. In Molecular & cellular proteomics : MCP 12 (12), pp. 3778–3792. DOI: 10.1074/mcp.M113.029587.

Ratovitski, Tamara; Chighladze, Ekaterine; Waldron, Elaine; Hirschhorn, Ricky R.; Ross, Christopher A. (2011): Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. In The Journal of biological chemistry 286 (14), pp. 12578–12589. DOI: 10.1074/jbc.M110.185348.

Raveh, Avi; Delekta, Phillip C.; Dobry, Craig J.; Peng, Weiping; Schultz, Pamela J.; Blakely, Pennelope K. et al. (2013): Discovery of potent broad spectrum antivirals derived from marine actinobacteria. In PloS one 8 (12), e82318. DOI: 10.1371/journal.pone.0082318.

Reddy, Marpadga A.; Das, Sadhan; Zhuo, Chen; Jin, Wen; Wang, Mei; Lanting, Linda; Natarajan, Rama (2016): Regulation of Vascular Smooth Muscle Cell Dysfunction Under Diabetic Conditions by miR-504. In Arteriosclerosis, thrombosis, and vascular biology 36 (5), pp. 864–873. DOI: 10.1161/ATVBAHA.115.306770.

Richard, David J.; Lena, Ryan; Bannister, Thomas; Blake, Noel; Pierceall, William E.; Carlson, Nicole E. et al. (2013): Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. In Bioorganic & medicinal chemistry 21 (21), pp. 6642–6649. DOI: 10.1016/j.bmc.2013.08.017.

Rivera, Barbara; Gayden, Tenzin; Carrot-Zhang, Jian; Nadad, Javad; Boshari, Talia; Faury, Damien et al. (2016): Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. In Acta neuropathologica 131 (6), pp. 847–863. DOI: 10.1007/s00401-016-1549-x.

Rao, R.; Hossain, M. M.; Christopherson, J.; Free, C.; Jain, S.; Guay, C. et al. (2017): Identification and Characterization of microRNAs Associated With Human β-Cell Loss in a Mouse Model. In American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 17 (4), pp. 992–1007. DOI: 10.1111/ajt.14073.

Rong, Rong; Yang, Hui; Rong, Liangqun; Wei, Xiue; Li, Qingjie; Liu, Xiaomei et al. (2016): Proteomic analysis of PSD-93 knockout mice following the induction of ischemic cerebral injury. In Neurotoxicology 53, pp. 1–11. DOI: 10.1016/j.neuro.2015.12.005.

Roselló-Lletí, Esther; Tarazón, Estefanía; Barderas, María G.; Ortega, Ana; Molina-Navarro, María Micaela; Martínez, Alba et al. (2015): ATP synthase subunit alpha and LV mass in ischaemic human hearts. In Journal of cellular and molecular medicine 19 (2), pp. 442–451. DOI: 10.1111/jcmm.12477.

Rossi, Andrea; Gauvrit, Sebastien; Marass, Michele; Pan, Luyuan; Moens, Cecilia B.; Stainier, Didier Y. R. (2016): Regulation of Vegf signaling by natural and synthetic ligands. In Blood 128 (19), pp. 2359–2366. DOI: 10.1182/blood-2016-04-711192.

Rouhier, Matthew F.; Raphemot, Rene; Denton, Jerod S.; Piermarini, Peter M. (2014): Pharmacological validation of an inward-rectifier potassium (Kir) channel as an insecticide target in...
the yellow fever mosquito *Aedes aegypti*. In *PloS one* 9 (6), e100700. DOI: 10.1371/journal.pone.0100700.

Rozenberg, Konstantin; Smirin, Polina; Sampson, Sanford R.; Rosenzweig, Tovit (2014): Insulin-sensitizing and insulin-mimetic activities of *Sarcopoterium spinosum* extract. In *Journal of ethnopharmacology* 155 (1), pp. 362–372. DOI: 10.1016/j.jep.2014.05.030.

Ruiz-Riol, M.; Berdnik, D.; Llano, A.; Mothe, B.; Gálvez, C.; Pérez-Álvarez, S. et al. (2017): Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control. In *Journal of virology* 91 (16). DOI: 10.1128/JVI.00441-17.

Rustenhoven, Justin; Aalderink, Miranda; Scatter, Emma L.; Oldfield, Robyn L.; Bergin, Peter S.; Mee, Edward W. et al. (2016): TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. In *Journal of neuroinflammation* 13, p. 37. DOI: 10.1186/s12974-016-0503-0.

Sakamoto, Kazuhito; Wehde, Barbara L.; Yoo, Kyung Hyun; Kim, Taemook; Rajbhandari, Nirakar; Shin, Ha Youn et al. (2016): Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling. In *Molecular and cellular biology* 36 (11), pp. 1673–1690. DOI: 10.1128/MCB.00999-15.

Saklani, Arvind; Hegde, Bindu; Mishra, Prabha; Singh, Ruchi; Mendon, Monica; Chakrabarty, Debarshi et al. (2012): NF-kB dependent anti-inflammatory activity of chlorojarnerin isolated from *Saussurea heteromalla*. In *Phytomedicine* : international journal of phytotherapy and phytopharmacology 19 (11), pp. 988–997. DOI: 10.1016/j.phymed.2012.05.016.

Sakowski, Stacey A.; Lunn, J. Simon; Busta, Angela S.; Oh, Sang Su; Zamora-Berridi, Grettel; Palmer, Madeline et al. (2012): Neuromuscular effects of G93A-SOD1 expression in zebrafish. In *Molecular neurodegeneration* 7, p. 44. DOI: 10.1186/1750-1326-7-44.

Salm, Fabiana; Dimitrova, Valeriya; Bueren, André O. von; Ćwiek, Paulina; Rehrauer, Hubert; Djonov, Valentin et al. (2015): The Phosphoinositide 3-Kinase p110alpha Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. In *PloS one* 10 (4), e0123958. DOI: 10.1371/journal.pone.0123958.

Samad, Omar A.; Tan, Andrew M.; Cheng, Xiaoyang; Foster, Edmund; Dib-Hajj, Sulayman D.; Waxman, Stephen G. (2013): Virus-mediated shRNA knockdown of Na(v)1.3 in rat dorsal root ganglion attenuates nerve injury-induced neuropathic pain. In *Molecular therapy : the journal of the American Society of Gene Therapy* 21 (1), pp. 49–56. DOI: 10.1038/mt.2012.169.

Sanders, Laurie H.; Laganère, Josée; Cooper, Oliver; Mak, Sally K.; Vu, B. Joseph; Huang, Y. Anne et al. (2014): LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. In *Neurobiology of disease* 62, pp. 381–386. DOI: 10.1016/j.nbd.2013.10.013.

Scherr, M.; Elder, A.; Battmer, K.; Barzan, D.; Bomken, S.; Ricke-Hoch, M. et al. (2014): Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. In *Leukemia* 28 (3), pp. 554–565. DOI: 10.1038/leu.2013.361.

Schliesser, Maximilian Georg; Claus, Rainer; Hielscher, Thomas; Grimm, Christiane; Weichenhan, Dieter; Blaes, Jonas et al. (2016): Prognostic relevance of miRNA-155 methylation in anaplastic glioma. In *Oncotarget* 7 (50), pp. 82028–82045. DOI: 10.18632/oncotarget.13452.

Schmidt, Constanze; Wiedmann, Felix; Gaubatz, Anne-Rike; Ratte, Antonius; Katus, Hugo A.; Thomas, Dierk (2018): New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K2P3.1 (TASK-1)
Channels. In The Journal of pharmacology and experimental therapeutics 365 (3), pp. 614–623. DOI: 10.1124/jpet.118.247692.

Schmitz, Karl R.; Sauer, Robert T. (2014): Substrate delivery by the AAA+ ClpX and ClpC1 unfoldases activates the mycobacterial ClpP1P2 peptidase. In Molecular microbiology 93 (4), pp. 617–628. DOI: 10.1111/mmi.12694.

Schwartz, Nika; Pellach, Michal; Glick, Yair; Gil, Reuven; Levy, Gahl; Avrahami, Dorit et al. (2018): Neuregulin 1 discovered as a cleavage target for the HCV NS3/4A protease by a microfluidic membrane protein array. In New biotechnology 45, pp. 113–122. DOI: 10.1016/j.nbt.2018.02.004.

Scott, Robert A.; Freitag, Daniel F.; Li, Li; Chu, Audrey Y.; Surendran, Praveen; Young, Robin et al. (2016): A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. In Science translational medicine 8 (341), 341ra76. DOI: 10.1126/scitranslmed.aad3744.

Shah, Gul N.; Price, Tulin O.; Banks, William A.; Morofuji, Yoichi; Kovac, Andrej; Ercal, Nuran et al. (2013): Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis. In The Journal of pharmacology and experimental therapeutics 344 (3), pp. 637–645. DOI: 10.1124/jpet.112.201400.

Sharma, Vibha; Fretwell, Deborah; Crees, Zachary; Kerege, Anna; Klopper, Joshua P. (2010): Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism. In Thyroid : official journal of the American Thyroid Association 20 (10), pp. 1103–1111. DOI: 10.1089/thy.2010.0096.

She, Sha; Yang, Min; Hu, Huaidong; Hu, Peng; Yang, Yixuan; Ren, Hong (2018): Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration. In Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 45 (2), pp. 744–760. DOI: 10.1159/000487166.

Shi, Jinlong; Chen, Xia; Li, Haiying; Wu, Youjia; Wang, Shouyan; Shi, Wei et al. (2017): Neuron-autonomous transcriptome changes upon ischemia/reperfusion injury. In Scientific reports 7 (1), p. 5800. DOI: 10.1038/s41598-017-05342-9.

Shimato, Shinji; Anderson, Lisa M.; Asslaber, Martin; Bruce, Jeffrey N.; Canoll, Peter; Anderson, David E.; Anderson, Richard C. E. (2013): Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma. In PloS one 8 (10), e77397. DOI: 10.1371/journal.pone.0077397.

Shoshan, Einav; Braeuer, Russell R.; Kamiya, Takafumi; Mobley, Aaron K.; Huang, Li; Vasquez, Mayra E. et al. (2016): NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis. In Cancer research 76 (11), pp. 3145–3155. DOI: 10.1158/0008-5472.CAN-15-2511.

Simpson, Nicholas; Gatenby, Paul A.; Wilson, Anastasia; Malik, Shreya; Fulcher, David A.; Tangye, Stuart G. et al. (2010): Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. In Arthritis and rheumatism 62 (1), pp. 234–244. DOI: 10.1002/art.25032.

Sims, Jennifer Nicole; Graham, Barbara; Pacurari, Maricica; Leggett, Sophia S.; Tchounwou, Paul B.; Ndebele, Kenneth (2014): Di-ethylhexylphthalate (DEHP) modulates cell invasion, migration and anchorage independent growth through targeting S100P in LN-229 glioblastoma cells. In International journal of environmental research and public health 11 (5), pp. 5006–5019. DOI: 10.3390/ijerph110505006.
Singh, Lata; Saini, Neeru; Pushker, Neelam; Sen, Seema; Sharma, Anjana; Kashyap, Seema (2016): Prognostic significance of NADPH oxidase-4 as an indicator of reactive oxygen species stress in human retinoblastoma. In International journal of clinical oncology 21 (4), pp. 651–657. DOI: 10.1007/s10147-016-0951-7.

Slotta, Carsten; Schützer, Thomas; Ruiz-Perera, Lucia M.; Kadhim, Hussamadin M.; Tertel, Tobias; Henkel, Elena et al. (2017): CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. In PloS one 12 (8), e0182373. DOI: 10.1371/journal.pone.0182373.

Song, Hyunkeun; Han, Il-Yong; Kim, Yeonye; Kim, Young Hwan; Choi, Il-Whan; Seo, Su-Kil et al. (2015): The NADPH oxidase inhibitor DPI can abolish hypoxia-induced apoptosis of human kidney proximal tubular epithelial cells through Bcl2 up-regulation via ERK activation without ROS reduction. In Life sciences 126, pp. 69–75. DOI: 10.1016/j.lfs.2015.02.004.

Stäubert, Claudia; Bhuiyan, Hasanuzzaman; Lindahl, Anna; Broom, Oliver Jay; Zhu, Yafeng; Islam, Saiful et al. (2015): Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarking by reduced dependence on exogenous glutamine. In The Journal of biological chemistry 290 (13), pp. 8348–8359. DOI: 10.1074/jbc.M114.618769.

Subramanian, Khaushik; Gianni, Davide; Balla, Cristina; Assenza, Gabriele Egidy; Joshi, Mugdha; Semigran, Marc J. et al. (2015): Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. In Journal of the American College of Cardiology 65 (12), pp. 1199–1214. DOI: 10.1016/j.jacc.2015.01.031.

Sudhaman, Sumedha; Muthane, Uday B.; Behari, Madhuri; Govindappa, Shyla T.; Juyal, Ramesh C.; Thelma, B. K. (2016): Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel
cause of autosomal-dominant Parkinson's disease with non-motor phenotypes. In Journal of medical genetics 53 (8), pp. 559–566. DOI: 10.1136/jmedgenet-2015-103616.

Sun, Li; Zhang, Xiaoxu; Dai, Fang; Shen, Jijia; Ren, Cuiping; Zuo, Chunlin; Zhang, Qiu (2016): Elevated interleukin-1β in peripheral blood mononuclear cells contributes to the pathogenesis of autoimmune thyroid diseases, especially of Hashimoto thyroiditis. In Endocrine research 41 (3), pp. 185–192. DOI: 10.3109/07435800.2015.1124439.

Sun, Shan-Shan; Zhou, Xuan; Huang, Yuan-Yuan; Kong, Ling-Ping; Mei, Mei; Guo, Wen-Yu et al. (2015): Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma. In Molecular cancer 14, p. 213. DOI: 10.1186/s12943-015-0487-x.

Sun, Yaping; Iyer, Matthew; McEachin, Richard; Zhao, Meng; Wu, Yi-Mi; Cao, Xuhong et al. (2017): Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. In Journal of innate immunity 9 (2), pp. 126–144. DOI: 10.1159/000450681.

Sun, Yuan-Xin; Li, Hui; Feng, Qi; Li, Xin; Yu, Ying-Yi; Zhou, Li-Wei et al. (2017): Dysregulated miR34a/diacylglycerol kinase ζ interaction enhances T-cell activation in acquired aplastic anemia. In Oncotarget 8 (4), pp. 6142–6154. DOI: 10.18632/oncotarget.14046.

Suryani, Santi; Bracken, Lauryn S.; Harvey, Richard C.; Sia, Keith C. S.; Carol, Hernan; Chen, I-Ming et al. (2015): Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. In Molecular cancer therapeutics 14 (2), pp. 364–374. DOI: 10.1158/1535-7163.MCT-14-0647.

Sutphin, Robert M.; Connelly, Sarah F.; Lee, Chris M.; Sankpal, Umesh T.; Eslin, Don; Khan, Moeez et al. (2014): Anti-leukemic response of a NSAID, tolfenamic acid. In Targeted oncology 9 (2), pp. 135–144. DOI: 10.1007/s11523-013-0274-9.

Szabat, Marta; Pourghaderi, Poya; Soukhatcheva, Galina; Verchere, C. Bruce; Warnock, Garth L.; Piret, James M.; Johnson, James D. (2011): Kinetics and genomic profiling of adult human and mouse β-cell maturation. In Islets 3 (4), pp. 175–187. DOI: 10.4161/isl.3.4.15881.

Szulzewsky, Frank; Pelz, Andreas; Feng, Xi; Synowitz, Michael; Markovic, Darko; Langmann, Thomas et al. (2015): Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. In PloS one 10 (2), e0116644. DOI: 10.1371/journal.pone.0116644.

Tan, Andrew M.; Samad, Omar A.; Dib-Hajj, Sualityman D.; Waxman, Stephen G. (2015): Virus-Mediated Knockdown of Nav1.3 in Dorsal Root Ganglia of STZ-Induced Diabetic Rats Alleviates Tactile Allodynia. In Molecular medicine (Cambridge, Mass.) 21, pp. 544–552. DOI: 10.2119/molmed.2015.00063.

Tang, Yen-An; Wen, Wei-Ling; Chang, Jer-Wei; Wei, Tzi-Tang; Tan, Yi-Hung Carol; Salunke, Santosh et al. (2010): A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. In PloS one 5 (9), e12417. DOI: 10.1371/journal.pone.0012417.

Taniguchi, Junichi; Pandian, Ganesh N.; Hidaka, Takuya; Hashiya, Kaori; Bando, Toshikazu; Kim, Kyeong Kyu; Sugiyama, Hiroshi (2017): A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. In Nucleic acids research 45 (16), pp. 9219–9228. DOI: 10.1093/nar/gkx693.

Tarocchi, Mirko; Hannivoort, Rebekka; Hoshida, Yujin; Lee, Ursula E.; Vetter, Diana; Narla, Goutham et al. (2011): Carcinogen-induced hepatic tumors in KLF6+/− mice recapitulate aggressive human
hepatocellular carcinoma associated with p53 pathway deregulation. In Hepatology (Baltimore, Md.) 54 (2), pp. 522–531. DOI: 10.1002/hep.24413.

Tassi, Renata A.; Todeschini, Paola; Siegel, Eric R.; Calzina, Stefano; Cappella, Paolo; Ardighieri, Laura et al. (2017): FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. In Journal of experimental & clinical cancer research : CR 36 (1), p. 63. DOI: 10.1186/s13046-017-0536-y.

Taylor-Fishwick, David A.; Shi, Wenjing; Hughes, Laura; Vinik, Aaron (2010): Pdx-1 regulation of the INGAP promoter involves sequestration of NeuroD into a non-DNA-binding complex. In Pancreas 39 (1), pp. 64–70. DOI: 10.1097/MPA.0b013e3181baa0cc.

Teng, Jian; Hejazi, Seyedali; Hiddingh, Lotte; Carvalho, Litia; Gooijer, Mark C. de; Wakimoto, Hiroaki et al. (2018): Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. In Neuro-oncology 20 (5), pp. 642–654. DOI: 10.1093/neuonc/nox198.

Teodorczyk, M.; Kleber, S.; Wollny, D.; Sefrin, J. P.; Aykut, B.; Mateos, A. et al. (2015): CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. In Cell death and differentiation 22 (7), pp. 1192–1202. DOI: 10.1038/cdd.2014.217.

ter Braak, Bas; Wink, Steven; Koedoot, Esme; Pont, Chantal; Siezen, Christine; van der Laan, Jan Willem; van de Water, Bob (2015): Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells. In Breast cancer research : BCR 17, p. 97. DOI: 10.1186/s13058-015-0600-5.

Terajima, Masaomi; Kaneko-Kobayashi, Yoko; Nakamura, Naoto; Yuri, Masatoshi; Hiramoto, Masashi; Naitou, Masanori et al. (2016): Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor. In European journal of pharmacology 780, pp. 93–105. DOI: 10.1016/j.ejphar.2016.03.036.

Tseng, Sheng-Chieh; Huang, Yu-Ching; Chen, Huang-Jen; Chiu, Hsien-Chun; Huang, Yi-Jhen; Wo, Ting-Yu et al. (2013): Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. In Biochemical pharmacology 85 (4), pp. 583–594. DOI: 10.1016/j.bcp.2012.12.001.

Tubbs, Emily; Theurey, Pierre; Vial, Guillaume; Bendridi, Nadia; Bravard, Amélie; Chauvin, Marie-Agnés et al. (2014): Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. In Diabetes 63 (10), pp. 3279–3294. DOI: 10.2337/db13-1751.

Ussher, John R.; Wang, Wei; Gandhi, Manoj; Keung, Wendy; Samokhvalov, Victor; Oka, Tatsujiro et al. (2012): Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. In Cardiovascular research 94 (2), pp. 359–369. DOI: 10.1093/cvr/cvs129.

Vahedi, Shahrooz; Chueh, Fu-Yu; Chandran, Bala; Yu, Chao-Lan (2015): Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation. In BMC cancer 15, p. 551. DOI: 10.1186/s12885-015-1520-6.

van Horssen, Jack; van der Pol, Susanne; Nijland, Philip; Amor, Sandra; Perron, Hervé (2016): Human endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis. In Multiple sclerosis and related disorders 8, pp. 11–18. DOI: 10.1016/j.msard.2016.04.006.
van Scheppingen, Jackelien; Mills, James D.; Zimmer, Till S.; Broekaart, Diede W. M.; Iori, Valentina; Bongaarts, Anika et al. (2018): miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes. In Glia 66 (5), pp. 1082–1097. DOI: 10.1002/glia.23302.

van Vuurden, Dannis G.; Aronica, Eleonora; Hulleman, Esther; Wedekind, Laurine E.; Biesmans, Dennis; Malekzadeh, Arjan et al. (2014): Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. In Neuro-oncology 16 (7), pp. 946–959. DOI: 10.1093/neuonc/not308.

Venardos, Kylie; Jong, Kirstie A. de; Elkamie, Mansour; Connor, Timothy; McGee, Sean L. (2015): The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice. In PloS one 10 (3), e0120934. DOI: 10.1371/journal.pone.0120934.

Vita, Serena de; Schneider, Rebekka K.; Garcia, Michael; Wood, Jenna; Gavillet, Mathilde; Ebert, Benjamin L. et al. (2014): Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. In PloS one 9 (5), e96209. DOI: 10.1371/journal.pone.0096209.

Vivarini, Áislan de Carvalho; Calegari-Silva, Teresa Cristina; Saliba, Alessandra Mattos; Boaventura, Viviane Sampaio; França-Costa, Jaqueline; Khouri, Ricardo et al. (2017): Systems Approach Reveals Nuclear Factor Erythroid 2-Related Factor 2/Protein Kinase R Crosstalk in Human Cutaneous Leishmaniasis. In Frontiers in immunology 8, p. 1127. DOI: 10.3389/fimmu.2017.01127.

Wang, Jiachen; Dixon, Stacy E.; Ting, Li-Min; Liu, Ting-Kai; Jeffers, Victoria; Croken, Matthew M. et al. (2014): Lysine acetyltransferase GCN5b interacts with AP2 factors and is required for Toxoplasma gondii proliferation. In PLoS pathogens 10 (1), e1003830. DOI: 10.1371/journal.ppat.1003830.

Wang, Jie; You, Jialing; Wang, Lekai; Wang, Huimin; Tian, Tian; Wang, Wenjin et al. (2017): PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix. In Oncotarget 8 (43), pp. 74806–74819. DOI: 10.18632/oncotarget.20419.

Wang, Jing; Hu, Bo; Cao, Fei; Sun, Shenggang; Zhang, Yunjian; Zhu, Qing (2015): Down regulation of IncSCIR1 after spinal cord contusion injury in rat. In Brain research 1624, pp. 314–320. DOI: 10.1016/j.brainres.2015.07.052.

Wang, Linqian; Yang, Ming; Liao, Shijing; Liu, Wei; Dai, Gan; Wu, Guojun; Chen, Liyu (2017): Hsa-miR-27b is up-regulated in cytomegalovirus-infected human glioma cells, targets engrailed-2 and inhibits its expression. In Experimental biology and medicine (Maywood, N.J.) 242 (12), pp. 1227–1233. DOI: 10.1177/1535370217699535.

Wang, Peng; Xu, Jie; Hou, Zhiling; Wang, Fangfang; Song, Yingli; Wang, Jiao et al. (2016): miRNA-34a promotes proliferation of human pulmonary artery smooth muscle cells by targeting PDGFRA. In Cell proliferation 49 (4), pp. 484–493. DOI: 10.1111/cpr.12265.

Wang, Qiantao; Park, Jihyun; Devkota, Ashwini K.; Cho, Eun Jeong; Dalby, Kevin N.; Ren, Pengyu (2014): Identification and validation of novel PERK inhibitors. In Journal of chemical information and modeling 54 (5), pp. 1467–1475. DOI: 10.1021/ci500114r.

Wang, Qiaoshu; Zhang, Zhaoyun; Ding, Tianling; Chen, Zi; Zhang, Tao (2013): Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas. In Bioscience reports 33 (2), e00019. DOI: 10.1042/BSR20110124.

Wang, Rui; Shao, Fangyuan; Liu, Zhong; Zhang, Jiaxuan; Wang, Shaoliang; Liu, Jinyun et al. (2013): The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-xB and disruption of mitochondria-dependent pathways. In Chemical-biological interactions 205 (1), pp. 1–10. DOI: 10.1016/j.cbi.2013.06.007.
Wang, Xiang; Zuo, Dongjian; Yuan, Yufang; Yang, Xiaochun; Hong, Ze; Zhang, Rongrong (2017): MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. In Journal of cancer research and clinical oncology 143 (1), pp. 169–180. DOI: 10.1007/s00432-016-2277-2.

Wang, Xiaohong; Huang, Wei; Yang, Yang; Wang, Yigang; Peng, Tianqing; Chang, Jiang et al. (2014): Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. In Biochimica et biophysica acta 1842 (5), pp. 701–711. DOI: 10.1016/j.bbadis.2014.01.012.

Wang, Xiaotian; Wang, Lei; Guo, Shicheng; Bao, Yang; Ma, Yanyun; Yan, Fengyang et al. (2013): Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers. In FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27 (10), pp. 4194–4203. DOI: 10.1096/fj.13-229070.

Wang, Xiuchao; Wang, Shan; Wang, Wenting; Duan, Jianhong; Zhang, Ming; Lv, Xiaohua et al. (2016): A novel intrinsic analgesic mechanism: the enhancement of the conduction failure along polymodal nociceptive C-fibers. In Pain 157 (10), pp. 2235–2247. DOI: 10.1097/j.pain.0000000000000632.

Wang, Yan; Guo, Gang; Yang, Bin-Rui; Xin, Qi-Qi; Liao, Qi-Wen; Lee, Simon Ming-Yuen et al. (2017): Synergistic effects of Chuanxiong-Chishao herb pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels. In Chinese journal of integrative medicine 23 (9), pp. 654–662. DOI: 10.1007/s11655-017-2408-x.

Wang, Zhe; Xu, Panpan; Chen, Biyue; Zhang, Zhanyu; Zhang, Chunhu; Zhan, Qiong et al. (2018): Identifying circRNA-associated-ceRNA networks in the hippocampus of Aβ1-42-induced Alzheimer's disease-like rats using microarray analysis. In Aging 10 (4), pp. 775–788. DOI:10.18632/aging.101427.

Warrener, Paul; Varkey, Reena; Bonnell, Jessica C.; DiGiandomenico, Antonio; Camara, Maria; Cook, Kimberly et al. (2014): A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. In Antimicrobial agents and chemotherapy 58 (8), pp. 4384–4391. DOI: 10.1128/AAC.02643-14.

Wei, Ke; Pan, Chunfeng; Yao, Guoliang; Liu, Bin; Ma, Teng; Xia, Yang et al. (2017): MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer. In Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 44 (4), pp. 1545–1558. DOI: 10.1159/000485650.

Wei, Shuo; Yoshida, Nobuya; Finn, Greg; Kozono, Shingo; Nechama, Morris; Kyttar, Vasileios C. et al. (2016): Pin1-Targeted Therapy for Systemic Lupus Erythematosus. In Arthritis & rheumatology (Hoboken, N.J.) 68 (10), pp. 2503–2513. DOI: 10.1002/art.39741.

Weisberg, E.; Liu, Q.; Nelson, Erik; Kung, A. L.; Christie, A. L.; Bronson, R. et al. (2012): Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. In Leukemia 26 (10), pp. 2233–2244. DOI: 10.1038/leu.2012.96.

Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang et al. (2013): Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. In PloS one 8 (2), e56473. DOI: 10.1371/journal.pone.0056473.

Wermke, Martin; Camgoz, Aylin; Paszkowski-Rogacz, Maciej; Thieme, Sebastian; Bonin, Malte von; Dahl, Andreas et al. (2015): RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. In Blood 125 (24), pp. 3760–3768. DOI: 10.1182/blood-2014-07-590646.
Whetton, Anthony D.; Azmi, Norhaida Che; Pearson, Stella; Jaworska, Ewa; Zhang, Liqun; Blance, Rognvald et al. (2016): MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5. In Oncotarget 7 (10), pp. 10739–10755. DOI: 10.18632/oncotarget.7639.

Wood, Laurence M.; Pan, Zhen-Kun; Seavey, Matthew M.; Muthukumaran, Geetha; Paterson, Yvonne (2012): The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. In Cancer immunology, immunotherapy : CII 61 (5), pp. 689–700. DOI: 10.1007/s00262-011-1129-9.

Wu, Hongyu; Chen, Lihe; Zhang, Xi; Zhou, Qiaoling; Li, Ju-Mei; Berger, Stefan et al. (2013): Aqp5 is a new transcriptional target of Dot1a and a regulator of Aqp2. In PloS one 8 (1), e53342. DOI: 10.1371/journal.pone.0053342.

Wu, Jingjing; Zhang, Shizhen; Shan, Jinlan; Hu, Zujian; Liu, Xiyong; Chen, Lirong et al. (2016): Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. In Cancer letters 376 (2), pp. 284–292. DOI: 10.1016/j.canlet.2016.04.005.

Wu, Leibo; Beckebaum, Susanne; Iacob, Speranta; Wu, Gang; Kaiser, Gernot M.; Radtke, Arnold et al. (2014): MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. In Journal of hepatology 60 (3), pp. 590–598. DOI: 10.1016/j.jhep.2013.10.028.

Wu, Zhuojia; Diao, Zongli; Liu, Ruixia; Liu, Wenhu (2017): Molecular mechanism of smurf2 in regulating the expression of SnoN in diabetic nephropathy. In Molecular medicine reports 15 (5), pp. 2560–2566. DOI: 10.3892/mmr.2017.6307.

Xu, Xing-Xing; Liu, Xiao-Rong; Fan, Cui-Ying; Lai, Jin-Xing; Shi, Yi-Wu; Yang, Wei et al. (2018): Functional Investigation of a GRIN2A Variant Associated with Rolandoic Epilepsy. In Neuroscience bulletin 34 (2), pp. 237–246. DOI: 10.1007/s12264-017-0182-6.

Xu, Xunxun; Chen, Xiaofei; Dan, Jia; Cao, Yan; Gao, Shouhong; Guo, Zhiying et al. (2016): Characterization of anti-leukemia components from Indigo naturalis using comprehensive two-dimensional K562/cell membrane chromatography and in silico target identification. In Scientific reports 6, p. 25491. DOI: 10.1038/srep25491.

Xu, Jian; Cai, Rixin; Lu, Lu; Duan, Chengwei; Tao, Xuelei; Chen, Dongjian et al. (2014): Genetic regulatory network analysis reveals that low density lipoprotein receptor-related protein 11 is involved in stress responses in mice. In Psychiatry research 220 (3), pp. 1131–1137. DOI: 10.1016/j.psychres.2014.09.002.

Xu, Lei; Hazard, Florette K.; Zmoos, Anne-Flore; Jahchan, Nadine; Chaib, Hassan; Garfin, Phillip M. et al. (2015): Genomic analysis of fibrolamellar hepatocellular carcinoma. In Human molecular genetics 24 (1), pp. 50–63. DOI: 10.1093/hmg/ddu418.

Xu, Limei; Zhang, Mingming; Li, Hui; Guan, Wen; Liu, Bin; Liu, Fengqi et al. (2018): SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia. In Leukemia & lymphoma 59 (4), pp. 918–930. DOI: 10.1080/10428194.2017.1344843.

Xu, Zhuojaia; Diao, Zongli; Liu, Ruixia; Liu, Wenhu (2017): Molecular mechanism of smurf2 in regulating the expression of SnoN in diabetic nephropathy. In Molecular medicine reports 15 (5), pp. 2560–2566. DOI: 10.3892/mmr.2017.6307.

Yan, Jianguo; Zhang, Pei; Jiao, Fengjuan; Wang, Qingzhi; He, Feng; Zhang, Qian et al. (2017): Quantitative proteomics in A30P*A53T α-synuclein transgenic mice reveals upregulation of Sel1l. In PloS one 12 (8), e0182092. DOI: 10.1371/journal.pone.0182092.
Yang, Fan; Li, Haiyu; Du, Youyou; Shi, Qiangwei; Zhao, Luosha (2017): Downregulation of microRNA34b is responsible for the elevation of blood pressure in spontaneously hypertensive rats. In Molecular medicine reports 15 (3), pp. 1031–1036. DOI: 10.3892/mmr.2017.6122.

Yang, Lu; Niu, Fang; Yao, Honghong; Liao, Ke; Chen, Xufeng; Kook, Yeonhee et al. (2018): Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration. In Journal of neuroimmunology : the official journal of the Society on NeuroImmune Pharmacology 13 (3), pp. 330–344. DOI: 10.1007/s11481-018-9779-4.

Yang, Wei-Cheng; Hwang, Yih-Shiou; Chen, Ying-Yu; Liu, Chao-Lin; Shen, Chia-Ning; Hong, Wei-Hsin et al. (2017): Interleukin-4 Supports the Suppressive Immune Responses Elicited by Regulatory T Cells. In Frontiers in immunology 8, p. 1508. DOI: 10.3389/fimmu.2017.01508.

Yang, Yijun; Li, Fei; Saha, Manujendra N.; Abdi, Jahangir; Qiu, Lugui; Chang, Hong (2015): miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. In Clinical cancer research : an official journal of the American Association for Cancer Research 21 (10), pp. 2399–2411. DOI: 10.1158/1078-0432.CCR-14-1437.

You, Jieyun; Wu, Jian; Jiang, Guoliang; Guo, Jing; Wang, Shijun; Li, Lei et al. (2013): Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice. In Journal of cardiovascular pharmacology 61 (2), pp. 142–151. DOI: 10.1097/FJC.0b013e31827a0278.

Young, Martin E.; Brewer, Rachel A.; Peliciari-Garcia, Rodrigo A.; Collins, Helen E.; He, Lan; Birky, Tana L. et al. (2014): Cardiomyocyte-specific BMAL1 plays critical roles in metabolism, signaling, and maintenance of contractile function of the heart. In Journal of biological rhythms 29 (4), pp. 257–276. DOI: 10.1177/0748730414543141.

Yu, Dawei; Shi, Mengsong; Bao, Jinwei; Yu, Xinyan; Li, Yuhui; Liu, Wenbo (2016): Genipin ameliorates hypertension-induced renal damage via the angiotensin II-TLR/MyD88/MAPK pathway. In Fitoterapia 112, pp. 244–253. DOI: 10.1016/j.fitote.2016.06.010.

Zhang, Hongmin; Li, Hong; Yang, Yixuan; Li, Sanglin; Ren, Hong; Zhang, Dazhi; Hu, Huaidong (2013): Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. In Journal of proteome research 12 (6), pp. 2967–2979. DOI: 10.1021/pr400247f.

Zhang, Jiangbo; Cheng, Jin; Zeng, Zhenhen; Wang, Yongfeng; Li, Xiaojun; Xie, Qing et al. (2015): Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. In Oncotarget 6 (39), pp. 42040–42052. DOI: 10.18632/oncotarget.5969.

Zhang, Jiankai; He, Zhangyou; Guo, Jinhua; Li, Zhe; Wang, Xiaohong; Yang, Chun; Cui, Xiaojun (2016): Sulfiredoxin-1 protects against simulated ischaemia/reperfusion injury in cardiomyocyte by inhibiting PI3K/AKT-regulated mitochondrial apoptotic pathways. In Bioscience reports 36 (2). DOI: 10.1042/BSR20160076.
Zhang, Liren; Lin, Jing; Ye, Yuanqing; Oba, Taro; Gentile, Emanuela; Lian, Jie et al. (2018): Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. In Clinical pharmacology and therapeutics 103 (6), pp. 1061–1073. DOI: 10.1002 cpt.870.

Zhang, Liyun; Zheng, Yuchuan; Callahan, Brian; Belfort, Marlene; Liu, Yangzhong (2011): Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria. In The Journal of biological chemistry 286 (2), pp. 1277–1282. DOI: 10.1074/jbc.M110.171124.

Zhang, Ming; Robitaille, Mélanie; Showalter, Aaron D.; Huang, Xinyi; Liu, Ying; Bhattacharjee, Alpana et al. (2014): Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells. In Molecular & cellular proteomics : MCP 13 (11), pp. 3049–3062. DOI: 10.1074/mcp.M114.040196.

Zhang, Siwei; Fan, Gaofeng; Hao, Yuan; Hammell, Molly; Wilkinson, John Erby; Tonks, Nicholas K. (2017): Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase. In Genes & development 31 (19), pp. 1939–1957. DOI: 10.1101/gad.304261.117.

Zhang, Wei; Freichel, Marc; van der Hoeven, Frank; Nawroth, Peter Paul; Katus, Hugo; Kälble, Florian et al. (2016): Novel Endothelial Cell-Specific AQP1 Knockout Mice Confirm the Crucial Role of Endothelial AQP1 in Ultrafiltration during Peritoneal Dialysis. In PloS one 11 (1), e0145513. DOI: 10.1371/journal.pone.0145513.

Zhang, Xiaowei; Wang, Xiaohong; Zhu, Hongyan; Zhu, Cheng; Wang, Yigang; Pu, William T. et al. (2010): Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. In Journal of molecular and cellular cardiology 49 (5), pp. 841–850. DOI: 10.1016/j.yjmcc.2010.08.007.

Zhao, Yarong; Zhu, Haiyan; Wang, Haining; Xu, Lizhi; Chen, Dai et al. (2018): FC-99 ameliorates sepsis-induced liver dysfunction by modulating monocyte/macrophage differentiation via Let-7a related monocytes apoptosis. In Oncotarget 9 (19), pp. 14959–14976. DOI: 10.18632/oncotarget.24127.

Zheng, Lin; Fu, Yingying; Zhuang, Linhan; Gai, Renhua; Ma, Jian; Lou, Jianshu et al. (2014): Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo. In International journal of cancer 135 (7), pp. 1721–1732. DOI: 10.1002/ijc.28810.

Zheng, Y-S; Zhang, H.; Zhang, X-J; Feng, D-D; Luo, X-Q; Zeng, C-W et al. (2012): MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. In Oncogene 31 (1), pp. 80–92. DOI: 10.1038/onc.2011.208.

Zhou, Yue; Yan; Wang, Min; Ma, Qiang; Chen, Yundai (2018): Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway. In Cellular signalling 47, pp. 88–100. DOI: 10.1016/j.cellsig.2018.03.012.

Zhou, Jianbiao; Lu, Xiao; Tan, Tuan Zea; Chng, Wee-Joo (2018): X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery. In Molecular oncology 12 (1), pp. 33–47. DOI: 10.1002/1878-0261.12146.
Zhou, Xuan; Xu, Na; Li, Rong; Xiao, Yajuan; Gao, Guanlun; Lu, Qisi et al. (2015): A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells. In Leukemia & lymphoma 56 (7), pp. 2162–2169. DOI: 10.3109/10428194.2014.976818.

Zhou, Zhiyong; Wan, Lili; Han, Yonglong; Meng, Xiangle; Yang, Quanjun; Li, Yan et al. (2013): ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. In Pharmaceutical biology 51 (8), pp. 968–973. DOI: 10.3109/13880209.2013.772640.

Zhu, Xian; Ding, Hanying; Wang, Wengong; Liao, Zhicong; Fu, Zheng; Hong, Yeting et al. (2016): Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer. In Oncotarget 7 (19), pp. 28075–28085. DOI: 10.18632/oncotarget.8576.

Zhu, Kongkai; Jiang, Chengshi; Tao, Hongrui; Liu, Jingqiu; Zhang, Hua; Luo, Cheng (2018): Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations. In Bioorganic & medicinal chemistry letters 28 (9), pp. 1476–1483. DOI: 10.1016/j.bmcl.2018.03.087.

Zhuang, Jianguo; Hawkins, Stephen F.; Glenn, Mark A.; Lin, Ke; Johnson, Gillian G.; Carter, Anthony et al. (2010): Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. In Haematologica 95 (1), pp. 110–118. DOI: 10.3324/haematol.2009.010272.

Zimmer, Stephanie N.; Lemieux, Madeleine E.; Karia, Bijal P.; Day, Claudia; Zhou, Ting; Zhou, Qing et al. (2012): Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. In Experimental hematology 40 (4), 295-306.e5. DOI: 10.1016/j.exphem.2011.12.004.

Zou, Shuiyan; Ma, Cunying; Yang, Fenghua; Xu, Xia; Jia, Jihui; Liu, Zhifang (2018): FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation. In Molecular cancer research : MCR 16 (2), pp. 286–295. DOI: 10.1158/1541-7786.MCR-17-0432.